# Author Index For Volume 43


A

Abboud HE: Growth factors in glomerulonephritis (Nephrology Forum) ..... 252
Abdelhamid S *See* Röckel A et al ..... 41:S-67
Aboo O (abst) ..... 1179
Abraham AA *See* Kimmel PL et al ..... 1347
Abrahamson DR, St. John PL: Laminin distribution in developing glomerular basement membranes ..... 73
Abrahamson DR *See* Couchman JR et al ..... 79
Abrahamson DR *See* Minto AW et al ..... 121
Abrahamson DR *See* Weise WJ et al ..... 359
Abramo F (abst) ..... 754
Acton G (abst) ..... 967
Adhikari M (abst) ..... 1179
Ahmad S *See* Joven J et al ..... 410
Aiello S *See* Noris M et al ..... 426
Aimo G *See* Di Felice A et al ..... 41:S-201
Airaghi C (abst) ..... 762
Aizawa C *See* Nosaka K et al ..... 470
Akizawa T *See* Nakashima Y et al ..... 41:S-88
Albert E *See* Feucht HE et al ..... 1333
Albertazzi A (abst) ..... 757, 757
Albertazzi A, Palmieri PF, Mastrangelo E: Efficacy and tolerance of acetate free biofiltration: A central Italian multicenter trial ..... 41:S-188
Albouze G, Yanai M, Calamai M, Testou D, Jungers P, Man N-K, Robinet M: Urea rebound and residual renal function in the calculation of Kt/V and protein catabolic rate ..... 41:S-278
Albouze G *See* Caillat-Zucman S et al ..... 41:S-157
Albouze G *See* Jungers P et al ..... 41:S-170
Alessi D (abst) ..... 762
Alexander SR, Honda M: Continuous peritoneal dialysis for children: A decade of worldwide growth and development ..... 40:S-65
Alijani MR *See* Winchester JF et al ..... 40:S-101
Aljama P *See* Martin-Malo A et al ..... 41:S-213
Alloatti S (abst) ..... 761
Allon M: Treatment and prevention of hyperkalemia in end-stage renal disease (Editorial Review) ..... 1197
Allon M, Takeshian A, Shanklin N: Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia ..... 212
Alonso J *See* Egido J et al ..... 39:S-59
Alpers CE, Seifert RA, Hudkins KL, Johnson RJ, Bowen-Pope DF: PDGF-receptor localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys ..... 286
Alpert MA *See* Wizemann V et al ..... 40:S-85
Altieri P *See* Ponticelli C et al ..... 1377
Al-Uzri A *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Alvarez UM *See* Carlini RG et al ..... 1010
Amore A, Cavallo F, Bocchietto E, Bussolino F, Gianoglio B, Peruzzi L, Porcellini MG, Coppo R: Cytokine mRNA expression by cultured rat mesangial cells after contact with environmental lectins ..... 39:S-41
Amore A *See* Roccatello D et al ..... 1150
Amoroso L (abst) ..... 757
Amuchastegui CS *See* Ruggenenti P et al ..... 706
Ancarani P (abst) ..... 755
Anderson GF *See* Powe NR et al ..... 1125
Anderson S (abst) ..... 966
Andrassy K *See* Noronha IL et al ..... 682
Andrulli S (abst) ..... 754
Ang KS *See* Simon P et al ..... 41:S-291
Annat G *See* Bouffard Y et al ..... 1086
Antonelli M (abst) ..... 761
Aoyagi R, Miura Y, Ishiyama T, Maruyama Y, Hasegawa H: Influence of dialysis membranes on the development of dialysis associated osteoarthropathy ..... 41:S-111
Apperloo AJ (abst) ..... 969
Arakawa M *See* Gejyo F et al ..... 41:S-78
Arakawa M *See* Sato H et al ..... 430
Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration ..... 630
Argilés A *See* Canaud B et al ..... 41:S-296
Argy WP *See* Winchester JF et al ..... 41:S-174
Argy WP *See* Winchester JF et al ..... 40:S-101
Arisz L (abst) ..... 968, 969
Arisz L *See* Betjes MGH et al ..... 641
Arisz L *See* Imholz ALT et al ..... 1339
Armelloni S (abst) ..... 758, 761
Ashley CC *See* Raine AEG et al ..... 700
Assmann KJM (abst) ..... 968
Assmann KJM *See* Feith GW et al ..... 824
Assmann KJM *See* van den Born J et al ..... 454
Atala A, Freeman MR, Mandell J, Beier DR: Juvenile cystic kidneys (*jck*): A new mouse mutation which causes polycystic kidneys ..... 1081
Atkin C *See* Zhou J et al ..... 722
Atkins RC *See* Lan HY et al ..... 479
Atti M (abst) ..... 761
Audrain M *See* Esnault VLM et al ..... 1329
Augella F *See* Santoro A et al ..... 41:S-184
Aumailley M, Battaglia C, Mayer U, Reinhardt D, Nischt R, Timpl R, Fox JW: Nidogen mediates the formation of ternary complexes of basement membrane components ..... 7
Aupetit J *See* Chauveau P et al ..... 41:S-72
Avner ED (abst) ..... 966
Aya N *See* Takemura T et al ..... 918
Aynedjian HS *See* Bank N et al ..... 1306
Ayo SH *See* Kreisberg JI et al ..... 109

B

Bacchini G (abst) ..... 754
Baccino FM (abst) ..... 762
Bach J-F *See* Caillat-Zucman S et al ..... 41:S-157
Badenhorst PN (abst) ..... 1181, 1183
Baelde JJ (abst) ..... 968
Bakker MAH *See* van den Born J et al ..... 454
Bakris GL *See* Brown SA et al ..... 1210
Balk AAM (abst) ..... 969
Ballanti P (abst) ..... 760

# Author Index For Volume 43


A

Abboud HE: Growth factors in glomerulonephritis (Nephrology Forum) ..... 252
Abdelhamid S *See* Röckel A et al ..... 41:S-67
Aboo O (abst) ..... 1179
Abraham AA *See* Kimmel PL et al ..... 1347
Abrahamson DR, St. John PL: Laminin distribution in developing glomerular basement membranes ..... 73
Abrahamson DR *See* Couchman JR et al ..... 79
Abrahamson DR *See* Minto AW et al ..... 121
Abrahamson DR *See* Weise WJ et al ..... 359
Abramo F (abst) ..... 754
Acton G (abst) ..... 967
Adhikari M (abst) ..... 1179
Ahmad S *See* Joven J et al ..... 410
Aiello S *See* Noris M et al ..... 426
Aimo G *See* Di Felice A et al ..... 41:S-201
Airaghi C (abst) ..... 762
Aizawa C *See* Nosaka K et al ..... 470
Akizawa T *See* Nakashima Y et al ..... 41:S-88
Albert E *See* Feucht HE et al ..... 1333
Albertazzi A (abst) ..... 757, 757
Albertazzi A, Palmieri PF, Mastrangelo E: Efficacy and tolerance of acetate free biofiltration: A central Italian multicenter trial ..... 41:S-188
Albouze G, Yanai M, Calamai M, Testou D, Jungers P, Man N-K, Robinet M: Urea rebound and residual renal function in the calculation of Kt/V and protein catabolic rate ..... 41:S-278
Albouze G *See* Caillat-Zucman S et al ..... 41:S-157
Albouze G *See* Jungers P et al ..... 41:S-170
Alessi D (abst) ..... 762
Alexander SR, Honda M: Continuous peritoneal dialysis for children: A decade of worldwide growth and development ..... 40:S-65
Alijani MR *See* Winchester JF et al ..... 40:S-101
Aljama P *See* Martin-Malo A et al ..... 41:S-213
Alloatti S (abst) ..... 761
Allon M: Treatment and prevention of hyperkalemia in end-stage renal disease (Editorial Review) ..... 1197
Allon M, Takeshian A, Shanklin N: Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia ..... 212
Alonso J *See* Egido J et al ..... 39:S-59
Alpers CE, Seifert RA, Hudkins KL, Johnson RJ, Bowen-Pope DF: PDGF-receptor localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys ..... 286
Alpert MA *See* Wizemann V et al ..... 40:S-85
Altieri P *See* Ponticelli C et al ..... 1377
Al-Uzri A *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Alvarez UM *See* Carlini RG et al ..... 1010
Amore A, Cavallo F, Bocchietto E, Bussolino F, Gianoglio B, Peruzzi L, Porcellini MG, Coppo R: Cytokine mRNA expression by cultured rat mesangial cells after contact with environmental lectins ..... 39:S-41
Amore A *See* Roccatello D et al ..... 1150
Amoroso L (abst) ..... 757
Amuchastegui CS *See* Ruggenenti P et al ..... 706
Ancarani P (abst) ..... 755
Anderson GF *See* Powe NR et al ..... 1125
Anderson S (abst) ..... 966
Andrassy K *See* Noronha IL et al ..... 682
Andrulli S (abst) ..... 754
Ang KS *See* Simon P et al ..... 41:S-291
Annat G *See* Bouffard Y et al ..... 1086
Antonelli M (abst) ..... 761
Aoyagi R, Miura Y, Ishiyama T, Maruyama Y, Hasegawa H: Influence of dialysis membranes on the development of dialysis associated osteoarthropathy ..... 41:S-111
Apperloo AJ (abst) ..... 969
Arakawa M *See* Gejyo F et al ..... 41:S-78
Arakawa M *See* Sato H et al ..... 430
Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration ..... 630
Argilés A *See* Canaud B et al ..... 41:S-296
Argy WP *See* Winchester JF et al ..... 41:S-174
Argy WP *See* Winchester JF et al ..... 40:S-101
Arisz L (abst) ..... 968, 969
Arisz L *See* Betjes MGH et al ..... 641
Arisz L *See* Imholz ALT et al ..... 1339
Armelloni S (abst) ..... 758, 761
Ashley CC *See* Raine AEG et al ..... 700
Assmann KJM (abst) ..... 968
Assmann KJM *See* Feith GW et al ..... 824
Assmann KJM *See* van den Born J et al ..... 454
Atala A, Freeman MR, Mandell J, Beier DR: Juvenile cystic kidneys (*jck*): A new mouse mutation which causes polycystic kidneys ..... 1081
Atkin C *See* Zhou J et al ..... 722
Atkins RC *See* Lan HY et al ..... 479
Atti M (abst) ..... 761
Audrain M *See* Esnault VLM et al ..... 1329
Augella F *See* Santoro A et al ..... 41:S-184
Aumailley M, Battaglia C, Mayer U, Reinhardt D, Nischt R, Timpl R, Fox JW: Nidogen mediates the formation of ternary complexes of basement membrane components ..... 7
Aupetit J *See* Chauveau P et al ..... 41:S-72
Avner ED (abst) ..... 966
Aya N *See* Takemura T et al ..... 918
Aynedjian HS *See* Bank N et al ..... 1306
Ayo SH *See* Kreisberg JI et al ..... 109

B

Bacchini G (abst) ..... 754
Baccino FM (abst) ..... 762
Bach J-F *See* Caillat-Zucman S et al ..... 41:S-157
Badenhorst PN (abst) ..... 1181, 1183
Baelde JJ (abst) ..... 968
Bakker MAH *See* van den Born J et al ..... 454
Bakris GL *See* Brown SA et al ..... 1210
Balk AAM (abst) ..... 969
Ballanti P (abst) ..... 760

Ballerini L (abst) ..... 754
Ballieux BEPB (abst) ..... 971
Bank N, Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration ..... 1306
Barash BD *See* Cowley BD Jr. et al ..... 522
Barbour L (abst) ..... 1182
Baretta A (abst) ..... 754, 761
Baretto S *See* Durozard D et al ..... 885
Bargman JM: Complications of peritoneal dialysis related to increased intraabdominal pressure ..... 40:S-75
Barker DF *See* Zhou J et al ..... 722
Barlassina C (abst) ..... 757, 757
Barrier JH *See* Esnault VLM et al ..... 1329
Barsotti G (abst) ..... 756
Barsotti P (abst) ..... 754
Barth RH: Urea modeling and Kt/V: A critical appraisal ..... 41:S-252
Bason LM *See* Sizeland PCB et al ..... 448
Bastakis M *See* Maragoudakis ME et al ..... 147
Bates W (abst) ..... 1184, 1187, 1187, 1188
Battaglia C *See* Aumailley M et al ..... 7
Baverel G *See* Durozard D et al ..... 885
Bayle F *See* Cordonnier D et al ..... 41:S-8
Beale PG (abst) ..... 1189
Beathard GA: Gianturco self-expanding stent in the treatment of stenosis in dialysis access grafts ..... 872
Beccari M (abst) ..... 755
Becker M (abst) ..... 1185
Bedford L *See* Raine AEG et al ..... 700
Beekhuis H (abst) ..... 972
Beelen RHJ *See* Betjes MGH et al ..... 641
Beer JC *See* Kwan JTC et al ..... 1104
Beier DR *See* Ataia A et al ..... 1081
Belardi P *See* Piccoli G et al ..... 41:S-282
Bellon G *See* Borel JP et al ..... 26
Bello-Reuss E, Cabell-Kluch L, Pan Y: Characterization of acid-base transport mechanisms in the kidney cell line RCCT-28A ..... 173
Bello-Reuss E, Cabell-Kluch L, Tyler P: Characterization of peanut-lectin (+) cells derived from the RCCT-28A cell line ..... 182
Beltrame G *See* Piccoli GB et al ..... 41:S-14
Bemelman FJ *See* Raasveld MHM et al ..... 1140
Benatti L *See* Orisio S et al ..... 354
Bendinelli M (abst) ..... 754
Bending MR *See* Foxall PJD et al ..... 234
Benfenati E *See* Noris M et al ..... 426
Benhamou P-Y *See* Cordonnier D et al ..... 41:S-8
Benigni A *See* Noris M et al ..... 426
Benigni A *See* Orisio S et al ..... 354
Benigni A *See* Ruggenenti P et al ..... 706
Benstein JA *See* Dworkin LD et al ..... 808
Benz RL *See* Pressman MR et al ..... 1134
Benziane A *See* Simon P et al ..... 41:S-291
Berden JHM *See* van den Born J et al ..... 454
Bergia R (abst) ..... 761
Bergijk EC (abst) ..... 968
Bergström J (abst) ..... 755
Bergström J: Nutrition and adequacy of dialysis in hemodialysis patients ..... 41:S-261
Bergström J, Lindholm B: Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? ..... 40:S-39
Berlin JA *See* Feldman HI et al ..... 1091
Berliner RW: Remembering Homer Smith ..... 171
Bernasconi P (abst) ..... 761
Berndt TJ *See* Isaac J et al ..... 1021
Bernich P (abst) ..... 758
Bertrand O *See* Bouffard Y et al ..... 1086
Betjes MGH, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hoefsmit ECM, Beelen RHJ: Immuno-effector characteristics of peritoneal cells during CAPD treatment: A longitudinal study ..... 641
Better OS: Acute renal failure in casualties of mass disasters ..... 41:S-235
Beynon HLC *See* Ryan JJ et al ..... 41:S-226
Bianchi G (abst) ..... 757, 757, 763
Bianchi L (abst) ..... 757
Bianchi M (abst) ..... 755
Biancone L *See* Camussi G et al ..... 39:S-32
Biancone L *See* Tetta C et al ..... 39:S-154
Bibiano L *See* Carletti P et al ..... 41:S-70
Bidani A *See* Schwartz MM et al ..... 610
Bindels RJM, Dempster JA, Ramakers PLM, Willems PHGM, van Os CH: Effect of protein kinase C activation and down-regulation on active calcium transport ..... 295
Bindels RJM *See* Koster HPG et al ..... 828
Blake PG *See* Lindsay RM et al ..... 41:S-268
Blankestijn PJ (abst) ..... 969
Bloom RD, Florquin S, Singer GG, Brennan DC, Kelley VR: Colony stimulating factor-1 in the induction of lupus nephritis ..... 1000
Boccardo P *See* Noris M et al ..... 426
Bocchietto E *See* Amore A et al ..... 39:S-41
Bodénès-Dueymes M *See* Dueymes JM et al ..... 41:S-161
Boer P *See* Boer WH et al ..... 301
Boer WH, Fransen R, Boer P, de Roos R, Koomans HA: Prostaglandin synthesis inhibition stimulates lithium reabsorption in the Henle's loop in rats ..... 301
Boggi R *See* Carletti P et al ..... 41:S-70
Bogman MJJT (abst) ..... 968
Bogman MJJT *See* Feith GW et al ..... 824
Bolino A (abst) ..... 758
Bollini P (abst) ..... 757, 757
Bolzani R *See* Santoro A et al ..... 41:S-184
Bondatti F (abst) ..... 760
Bonello F *See* Piccoli G et al ..... 41:S-282
Bonello F *See* Piccoli GB et al ..... 41:S-14
Bongiorno P (abst) ..... 761
Bonn F *See* Simon P et al ..... 41:S-291
Bonomini V (abst) ..... 756, 759
Bonucci E (abst) ..... 760
Bonventre JV: Mechanisms of ischemic acute renal failure (Nephrology Forum) ..... 1160
Borca M *See* Piccoli G et al ..... 41:S-282
Borca M *See* Piccoli GB et al ..... 41:S-14
Border WA *See* Humes HD et al ..... 575
Bordone C (abst) ..... 762
Borel JP, Bellon G, Garnotel R, Monboisse JC: Adhesion and activation of human neutrophils on basement membrane molecules ..... 26
Borghi M *See* Santoro A et al ..... 41:S-184
Borgnino LC (abst) ..... 756, 759
Bosch RJ *See* Woolf AS et al ..... 39:S-116
Boswell RN (abst) ..... 970
Botden L (abst) ..... 1180
Botha BP (abst) ..... 1179, 1181, 1183, 1183
Botha JR (abst) ..... 1187, 1190
Botha RA (abst) ..... 1185
Bottalico D *See* Pertosa G et al ..... 39:S-149

Bouffard Y, Tissot S, Delafosse B, Viale JP, Annat G, Bertrand O, Motin J: Metabolic effects of hemodialysis with and without glucose in the dialysate ..... 1086
Bourgeon B *See* Moriniere P et al ..... 41:S-121
Bowen JW *See* Yordy MR et al ..... 940
Bowen-Pope DF *See* Alpers CE et al ..... 286
Braam B (abst) ..... 970
Breedveld FC (abst) ..... 966, 971
Brennan DC *See* Bloom RD et al ..... 1000
Brenner BM (abst) ..... 966
Bresnahan BA *See* Wu S-H et al ..... 1280
Briganti M *See* Santoro A et al ..... 41:S-184
Britten D (abst) ..... 1186
Brown AJ *See* Finch JL et al ..... 561
Brown PD, Kleiner DE, Unsworth EJ, Stetler-Stevenson WG: Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex ..... 163
Brown R *See* Raine AEG et al ..... 700
Brown SA, Walton CL, Crawford P, Bakris GL: Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria ..... 1210
Brownlee M *See* Silbiger S et al ..... 853
Bruggeman LA, Pellicoro JA, Horigan EA, Klotman PE: Thromboxane and prostacyclin differentially regulate murine extracellular matrix gene expression ..... 1219
Bruijn JA (abst) ..... 966, 967, 968
Bruijn JA *See* van Velthuysen M-LF et al ..... 623
Brunati C (abst) ..... 754
Bruni F (abst) ..... 761
Brunori G (abst) ..... 755
Brunori G *See* Hirschberg R et al ..... 387
Brunori G *See* Maiorca R et al ..... 40:S-4
Brunzell JD *See* Joven J et al ..... 410
Bruyn JA *See* Yard BA et al ..... 39:S-133
Bruzzi I *See* Orisio S et al ..... 354
Bruzzi I *See* Ruggenenti P et al ..... 706
Burdick JF *See* Solez K et al ..... 1058
Burke TJ *See* Kribben A et al ..... 464
Burkhardt K *See* Feucht HE et al ..... 1333
Burtis WJ *See* Orloff JJ et al ..... 1371
Buscaroli A (abst) ..... 756
Bushinsky DA *See* Kim M et al ..... 189
Bussolino F *See* Amore A et al ..... 39:S-41
Bustos C *See* Egido J et al ..... 39:S-59
Butkowski RJ *See* Crary GS et al ..... 140
Byrne M (abst) ..... 1183


C


Cabell-Kluch L *See* Bello-Reuss E et al ..... 173
Cabell-Kluch L *See* Bello-Reuss E et al ..... 182
Cacace G (abst) ..... 762
Caglioti A *See* De Nicola L et al ..... 307
Cagnoli L *See* Santoro A et al ..... 41:S-184
Caillat-Zucman S, Giminez J-J, Albouze G, Lebkiri B, Naret C, Jungers P, Bach J-F: HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients ..... 41:S-157
Caillette A *See* Durozard D et al ..... 885
Cairoli O *See* Llach F et al ..... 899
Calamai M *See* Albouze G et al ..... 41:S-278
Calvet JP: Polycystic kidney disease: Primary extracellular matrix abnormality or defective cellular differentiation? ..... 101
Calvet JP *See* Cowley BD Jr. et al ..... 522
Cam G *See* Simon P et al ..... 41:S-291
Cambi V *See* Tetta C et al ..... 39:S-154
Cambridge G *See* Moodie FDL et al ..... 675
Camerini C (abst) ..... 755
Camerini C *See* Maiorca R et al ..... 40:S-4
Cameron JS *See* Schena FP et al ..... 39:S-1
Campbell RD *See* Sacks SH et al ..... 39:S-13
Camussi G, Mariano F, Biancone L, Montrucchio G, Vercellone A: Effect of cytokines on the cytoskeleton of resident glomerular cells ..... 39:S-32
Camussi G *See* Tetta C et al ..... 39:S-154
Canaud B, Kerr P, Argilés A, Flavier J-L, Stec F, Mion C: Is hemodiafiltration the dialysis modality of choice for the next decade? ..... 41:S-296
Canaud B *See* Argilés A et al ..... 630
Canavese C (abst) ..... 763
Canavese C *See* Pacitti A et al ..... 41:S-96
Cancarini G (abst) ..... 755
Cancarini GC *See* Maiorca R et al ..... 40:S-4
Canepa A (abst) ..... 755
Canino F *See* Tetta C et al ..... 39:S-154
Cappelli G *See* Di Felice A et al ..... 41:S-201
Cappellini MD (abst) ..... 754
Carletti P, Bibiano L, Boggi R, Taruscia D, Mioli V: Does anemia correction by rHuEPO improve uremic cardiopathy? ..... 41:S-70
Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M: Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells ..... 1010
Carrea A (abst) ..... 755
Carrio J *See* Oliva JA et al ..... 41:S-153
Casa-Alberighi OD *See* Ponticelli C et al ..... 1377
Caselli A (abst) ..... 761
Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, Ordinas A: Platelet activation on hemodialysis: Influence of dialysis membranes ..... 41:S-217
Casirati P (abst) ..... 757, 757, 763
Cassidy M (abst) ..... 1185
Cassidy MJD (abst) ..... 1181, 1190
Cassidy MJD *See* Ryan JJ et al ..... 41:S-226
Castellani A *See* Ponticelli C et al ..... 1377
Castiglione A (abst) ..... 755
Castillo D *See* Martin-Malo A et al ..... 41:S-213
Castronovo V *See* Cioce V et al ..... 30
Cataldi L (abst) ..... 762
Catto GRD *See* Khan IH et al ..... 41:S-143
Cattran DC, Fenton SSA: Contemporary management of renal failure: Outcome of the failed allograft recipient ..... 41:S-36
Catucci G (abst) ..... 757
Caudwell V *See* Chanard J et al ..... 41:S-83
Cavaliere G (abst) ..... 755
Cavalli G *See* Roccatello D et al ..... 39:S-144
Cavalli PL *See* Piccoli GB et al ..... 41:S-14
Cavallo F *See* Amore A et al ..... 39:S-41
Cernacek P *See* Levy M et al ..... 1236
Chadefaux B *See* Chauveau P et al ..... 41:S-72
Chambers ST *See* Sizeland PCB et al ..... 448
Chan JCM *See* Chan W et al ..... 790
Chan JCM *See* Metzger DL et al ..... 1042
Chan W, Valerie KC, Chan JCM: Expression of insulin-like growth factor-1 in uremic rats: Growth hormone resistance and nutritional intake ..... 790

Chanard J, Vincent C, Caudwell V, Lavaud S, Toupance O, Wong T, Revillard J-P: Beta 2-microglobulin metabolism in uremic patients who are undergoing dialysis ..... 41:S-83
Chandran PKG, Liggett R, Kirkpatrick B: Patient survival on PAN/AN69 membrane hemodialysis: A ten year analysis ..... 41:S-287
Chandrasekaran S *See* Tanzer ML et al ..... 66
Chapuy MC *See* Moriniere P et al ..... 41:S-121
Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients ..... 41:S-72
Chauveau P, Courouce A-M, Lemarec N, Naret C, Poignet J-L, Girault A, Ramdame M, Delons S: Antibodies to hepatitis C virus by second generation test in hemodialyzed patients ..... 41:S-149
Chauveau P *See* Descamps-Latscha B et al ..... 878
Cheli V (abst) ..... 762
Chen VK *See* Craelius W et al ..... 535
Chen WY *See* Yang C-W et al ..... 39:S-90
Cheng IKP *See* Nissenson AR et al ..... 40:S-120
Cheriex EC *See* Leunissen KML et al ..... 41:S-50
Cheung AK, Parker CJ, Hohnholt M: $\beta_2$ integrins are required for neutrophil degranulation induced by hemodialysis membranes ..... 649
Cheung MC *See* Joven J et al ..... 410
Chmielewski D *See* Rosenberg ME et al ..... 601
Chomant J *See* Majdalani G et al ..... 41:S-131
Christensen EI *See* Cui S et al ..... 796
Christensen S *See* Yusufi ANK et al ..... 1074
Chung AE, Dong L-J, Wu C, Durkin ME: Biological functions of entactin ..... 13
Churchill DN: Comparative morbidity among hemodialysis and continuous ambulatory peritoneal dialysis patients ..... 40:S-16
Churchill M *See* Schwartz MM et al ..... 610
Churchill PC *See* Schwartz MM et al ..... 610
Ciafré SA (abst) ..... 759
Cianciaruso B *See* De Nicola L et al ..... 307
Cieslinski DA *See* Humes HD et al ..... 575
Cinotti GA (abst) ..... 758
Cinotti GA *See* Menè P et al ..... 585
Cioce V, Margulies IMK, Sobel ME, Castronovo V: Interaction between the 67 kilodalton metastasis-associated laminin receptor and laminin ..... 30
Civati G (abst) ..... 754
Cleary PA *See* Molitch ME et al ..... 668
Cloete FC (abst) ..... 1183
Coburn JW: Mineral metabolism and renal bone disease: Effects of CAPD versus hemodialysis ..... 40:S-92
Coen G (abst) ..... 760
Coles GA *See* Topley N et al ..... 226
Collier IE *See* Strongin AY et al ..... 158
Colombo T *See* Rabl H et al ..... 912
Colturi C (abst) ..... 755, 761
Colussi G (abst) ..... 756, 762
Conley S *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Conte G *See* De Nicola L et al ..... 307
Conti M *See* Yamaki M et al ..... 1286
Coovadia HM (abst) ..... 1179
Coppo R *See* Amore A et al ..... 39:S-41
Coppo R *See* Roccatello D et al ..... 1150
Cordonnier D, Bayle F, Benhamou P-Y, Milongo R, Zaoui P, Maynard C, Halimi S: Future trends of management of renal failure in diabetics ..... 41:S-8
Coremans IEM (abst) ..... 966, 971
Corna D *See* Orisio S et al ..... 354
Cornia F *See* Di Felice A et al ..... 41:S-201
Corti M (abst) ..... 754
Cosci P *See* Malberti F et al ..... 41:S-125
Cosseddu D (abst) ..... 760
Couchman JR, Abrahamson DR, McCarthy KJ: Basement membrane proteoglycans and development ..... 79
Coudé M *See* Chauveau P et al ..... 41:S-72
Courouce A-M *See* Chauveau P et al ..... 41:S-149
Couser WG *See* Floege J et al ..... 369
Cowley BD Jr., Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH II: Autosomal-dominant polycystic kidney disease in the rat ..... 522
Craelius W, Ross MJ, Harris DR, Chen VK, Palant CE: Membrane currents controlled by physical forces in cultured mesangial cells ..... 535
Crary GS, Katz A, Fish AJ, Michael AF, Butkowski RJ: Role of a basement membrane glycoprotein in anti-tubular basement membrane nephritis ..... 140
Crawford P *See* Brown SA et al ..... 1210
Crowley S *See* Silbiger S et al ..... 853
Cui S, Flyvbjerg A, Nielsen S, Kiess W, Christensen EI: IGF-II/Man-6-P receptors in rat kidney: Apical localization in proximal tubule cells ..... 796
Cunningham J *See* Kwan JTC et al ..... 1104
Cupisti A (abst) ..... 756
Curatola G (abst) ..... 756
Cusi D (abst) ..... 757, 757

**D**

Daha MR (abst) ..... 966, 967, 967, 970, 971, 971
Daha MR *See* van den Dobbelsteen MEA et al ..... 544
Daha MR *See* Yard BA et al ..... 39:S-133
Dal Canton A *See* De Nicola L et al ..... 307
D'Alfonso S *See* Roccatello D et al ..... 39:S-144
d'Aloya G (abst) ..... 755
Damiani CQ (abst) ..... 761
D'Amico G (abst) ..... 758, 761, 763
Daniel TO *See* Marx M et al ..... 1027
Dann P *See* Orloff JJ et al ..... 1371
Davenport A, Davison AM, Will EJ: Membrane biocompatibility: Effects on cardiovascular stability in patients on hemofiltration ..... 41:S-230
Davenport A, Newton KE, Toothill C, Will EJ, Davison AM: Effect of aluminum mobilization on hemoglobin during the first six months after transplantation ..... 1313
Davenport A, Will EJ, Davison AM: Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure ..... 41:S-245
David S *See* Tetta C et al ..... 39:S-154
Davies M *See* Topley N et al ..... 226
Davison A *See* Lindsay RM et al ..... 41:S-1
Davison AM: Editorial: Complications arising in patients on long-term hemodialysis ..... 41:S-40
Davison AM *See* Davenport A et al ..... 1313
Davison AM *See* Davenport A et al ..... 41:S-230
Davison AM *See* Davenport A et al ..... 41:S-245
De Broe ME *See* Verstrepen WA et al ..... 1267
de Bruijn R (abst) ..... 972
De Cristofaro V (abst) ..... 754, 755, 761

De Feo T (abst) ..... 754
De Ferrari ME (abst) ..... 762
De Filippi PG (abst) ..... 762
de Groote D *See* Descamps-Latscha B et al ..... 878
de Heer E (abst) ..... 966, 968
de Heer E *See* van Velthuysen M-LF et al ..... 623
de Jager C (abst) ..... 1181
de Jong PE (abst) ..... 967, 969, 972
de Lissovoy G *See* Powe NR et al ..... 1125
De Micheli A (abst) ..... 762
de Neve W *See* Verbeelen D et al ..... 41:S-27
De Nicola L, Romano G, Memoli B, Cianciaruso B, Sabbatini M, Russo D, Caglioti A, Fuiano G, Dal Canton A, Conte G: Extra-natriuretic effects of atrial peptide in humans ..... 307
De Ridder L (abst) ..... 970
de Roos R *See* Boer WH et al ..... 301
De Sanctis LB (abst) ..... 756
De Stefanis D (abst) ..... 762
de Vries JPPM (abst) ..... 969
de Vries PMJM (abst) ..... 969
de Zeeuw D (abst) ..... 967, 969, 972
de Zeeuw D *See* Haas M et al ..... 949
Dean JW III *See* Tanzer ML et al ..... 66
Deen PMT (abst) ..... 966
Deen WM *See* Mayer G et al ..... 346
Deferrari G (abst) ..... 762
Deglise-Favre A *See* Tovey MG et al ..... 39:S-129
Dejana E, Raiteri M, Resnati M, Lampugnani MG: Endothelial integrins and their role in maintaining the integrity of the vessel wall ..... 61
Del Rosso G (abst) ..... 757
Delafosse B *See* Bouffard Y et al ..... 1086
Delgado O *See* Oliva JA et al ..... 41:S-153
Dello Russo A (abst) ..... 761
Delmez JA: Long-term complications of dialysis: Pathogenetic factors with special reference to bone ..... 41:S-116
Delons S *See* Chauveau P et al ..... 41:S-149
Demoz M (abst) ..... 762
Dempster JA (abst) ..... 966
Dempster JA *See* Bindels RJM et al ..... 295
der Niepen PV *See* Verbeelen D et al ..... 41:S-27
Derkx FHM (abst) ..... 969
Descamps-Latscha B, Herbelin A: Long-term dialysis and cellular immunity: A critical survey ..... 41:S-135
Descamps-Latscha B, Herbelin A, Nguyen AT, de Groote D, Chauveau P, Verger C, Jungers P, Zingraff J: Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysis ..... 878
Descombes E, Hanck AB, Fellay G: Water soluble vitamins in chronic hemodialysis patients and need for supplementation ..... 1319
deVries PMJM *See* Leunissen KML et al ..... 41:S-50
Di Benedetto A (abst) ..... 759
Di Cillo M *See* Montinaro V et al ..... 39:S-37
Di Felice A, Cappelli G, Facchini F, Tetta C, Cornia F, Aimo G, Lusvarghi E: Ultrafiltration and endotoxin removal from dialysis fluids ..... 41:S-201
Di Ieso N (abst) ..... 759
Di Liberato L (abst) ..... 757
Di Luca M (abst) ..... 759
Di Mario U *See* Menè P et al ..... 585
Di Paolo B (abst) ..... 757
Di Paolo S *See* Gesualdo L et al ..... 39:S-86
di studio Rene e Gravidanza Gruppo (abst) ..... 759
Diaz-Gallo C *See* Kelly VR et al ..... 39:S-108
Díez-Marqués ML *See* García-Escribano C et al ..... 324
Dinarello CA *See* Schindler R et al ..... 712
Divino Filho JC (abst) ..... 755
Docci D *See* Santoro A et al ..... 41:S-184
Dogliani M (abst) ..... 763
Dohi K *See* Horii Y et al ..... 39:S-71
Dong L-J *See* Chung AE et al ..... 13
Donker AJM (abst) ..... 969
Donker AJM *See* Leunissen KML et al ..... 41:S-50
Doorenbos C (abst) ..... 970
Dousa TP *See* Yamaki M et al ..... 1286
Dousa TP *See* Yusufi ANK et al ..... 1074
Dreesen J (abst) ..... 971
Drummer C *See* Lauster F et al ..... 41:S-57
Dueymes JM, Bodénès-Dueymes M, Mahé JL, Herman B: Detection of hepatitis B viral DNA by polymerase chain reaction in dialysis patients ..... 41:S-161
Dunham I *See* Sacks SH et al ..... 39:S-13
Durkin ME *See* Chung AE et al ..... 13
Durozard D, Pimmel P, Baretto S, Caillette A, Labeeuw M, Baverel G, Zech P: $^{31}P$ NMR spectroscopy investigation of muscle metabolism in hemodialysis patients ..... 885
Dussel R *See* Endlich K et al ..... 314
Dusso AS *See* Carlini RG et al ..... 1010
Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms ..... 808

**E**

Ebrahim O (abst) ..... 1181
Eckardt K-U, Koury ST, Tan CC, Schuster S, Kaissling B, Ratcliffe PJ, Kurtz A: Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia ..... 815
Edefonti A *See* Ponticelli C et al ..... 1377
Edelstein C (abst) ..... 1181, 1184
Edelstein CL (abst) ..... 1188
Edwards B *See* May R et al ..... 1156
Eggers PW *See* Powe NR et al ..... 1125
Egido J, Gómez-Chiarri M, Ortíz A, Bustos C, Alonso J, Gómez-Guerrero C, Gomez-Garre D, Lopez-Armada MJ, Plaza J, Gonzalez E: Role of tumor necrosis factor-$\alpha$ in the pathogenesis of glomerular diseases ..... 39:S-59
Egido J *See* Gómez-Chiarri M et al ..... 39:S-81
Egorin MJ *See* Heyman SN et al ..... 1226
Eiam-Ong S, Kurtzman NA, Sabatini S: Effect of furosemide-induced hypokalemic metabolic alkalosis on renal transport enzymes ..... 1015
Eliahou HE *See* Shulman LM et al ..... 1397
Emancipator SN *See* Schena FP et al ..... 39:S-1
Emmons RV *See* Humes HD et al ..... 575
Endlich K, Kühn R, Steinhausen M, Dussel R: Visualization of serotonin effects on renal vessels of rats ..... 314
Eng E *See* Floege J et al ..... 39:S-47
Eng E *See* Floege J et al ..... 369
Engelbrecht SJ (abst) ..... 1187
Engvall E: Laminin variants: Why, where and when? ..... 2
Enia G (abst) ..... 758
Epstein FH *See* Heyman SN et al ..... 1226
Escolar G *See* Cases A et al ..... 41:S-217

Esnault VLM, Testa A, Audrain M, Rogé C, Hamidou M, Barrier JH, Sesboüé R, Martin J-P, Lesavre P: Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis ..... 1329
Esper NE *See* Moriniere P et al ..... 41:S-121
Esterbauer H *See* Rabl H et al ..... 912

F

Fabbri C (abst) ..... 755
Fabris A (abst) ..... 758
Fabrizi F (abst) ..... 754
Facchini F *See* Di Felice A et al ..... 41:S-201
Fadda GZ, Thanakitcharu P, Smogorzewski M, Massry SG: Parathyroid hormone raises cytosolic calcium in pancreatic islets: Study on mechanisms ..... 554
Falbo E (abst) ..... 756
Faraggiana T (abst) ..... 758
Farkas-Szallasi T *See* Kimmel PL et al ..... 1347
Farquet C *See* Moriniere P et al ..... 41:S-121
Fasoli E (abst) ..... 760
Favus MJ *See* Kim M et al ..... 189
Feiner HD *See* Dworkin LD et al ..... 808
Feith GW (abst) ..... 968
Feith GW, Assmann KJM, Bogman MJJT, van Gompel APM, Schalkwijk J, Koene RAP: Lack of albuminuria in the early heterologous phase of anti-GBM nephritis in beige mice ..... 824
Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States ..... 1091
Feletti C (abst) ..... 759
Feletti C *See* Santoro A et al ..... 41:S-184
Fellay G *See* Descombes E et al ..... 1319
Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure (Editorial Review) ..... 771
Fenton SS *See* Sherrard DJ et al ..... 436
Fenton SSA *See* Cattran DC et al ..... 41:S-36
Ferioli A (abst) ..... 759
Feriozzi S (abst) ..... 758
Ferrari G *See* Santoro A et al ..... 41:S-184
Ferreira-Centeno A *See* Kimmel PL et al ..... 1347
Ferrero S (abst) ..... 763
Ferro M (abst) ..... 762
Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmüller G, Land W, Albert E: Capillary deposition of C4d complement fragment and early renal graft loss ..... 1333
Fiederling B (abst) ..... 757, 757
Fiegel P *See* Röckel A et al ..... 41:S-67
Fillit H *See* Kefalides NA et al ..... 94
Finch JL, Brown AJ, Kubodera N, Nishi Y, Slatopolsky E: Differential effects of 1,25-$(OH)_2D_3$ and 22-oxacalcitriol on phosphate and calcium metabolism ..... 561
Fine LG *See* Woolf AS et al ..... 39:S-116
Fingleson LM (abst) ..... 1190
Fioravanti G (abst) ..... 761
Fiorelli G (abst) ..... 754
Fioretto P *See* Lane PH et al ..... 661
Fish AJ *See* Crary GS et al ..... 140
Flavier JL *See* Argilés A et al ..... 630
Flavier J-L *See* Canaud B et al ..... 41:S-296
Fleuren GJ *See* van Velthuysen M-LF et al ..... 623
Floege J, Eng E, Young BA, Couser WG, Johnson RJ: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis ..... 369
Floege J, Eng E, Young BA, Johnson RJ: Factors involved in the regulation of mesangial cell proliferation *in vitro* and *in vivo* ..... 39:S-47
Florquin S *See* Bloom RD et al ..... 1000
Flyvbjerg A *See* Cui S et al ..... 796
Fockema MW (abst) ..... 1183
Fodero JP *See* Orloff JJ et al ..... 1371
Fogarty JF *See* Hricik DE et al ..... 398
Fogel MA *See* Minto AW et al ..... 121
Fogo A *See* Kakinuma Y et al ..... 1229
Fornasieri A (abst) ..... 758, 761
Fortuin G (abst) ..... 1180
Fournier A *See* Moriniere P et al ..... 41:S-121
Fox JW *See* Aumailley M et al ..... 7
Foxall PJD, Mellotte GJ, Bending MR, Lindon JC, Nicholson JK: NMR spectroscopy as a novel approach to the monitoring of renal transplant function ..... 234
Franceschini F (abst) ..... 759
Frankenschmidt A *See* Rump LC et al ..... 197
Fransen R *See* Boer WH et al ..... 301
Fransman A (abst) ..... 1186
Frascà GM (abst) ..... 759
Fray JCS *See* Lush DJ et al ..... 983
Freeman MR *See* Atala A et al ..... 1081
Frei U *See* Netzer K-O et al ..... 486
Frohlich JJ *See* Magil AB et al ..... 1243
Frolkis I *See* Shulman LM et al ..... 1397
Fuiano G *See* De Nicola L et al ..... 307
Fujigaki Y, Nagase M, Kobayasi S, Hidaka S, Shimomura M, Hishida A: Intra-GBM site of the functional filtration barrier for endogenous proteins in rats ..... 567
Fujii Y *See* Horii Y et al ..... 39:S-71
Fukiyama K *See* Iseki K et al ..... 404
Fülle H-J *See* Lauster F et al ..... 41:S-57
Fusaroli M *See* Santoro A et al ..... 41:S-184

G

Galisoff ML *See* Quigg RJ et al ..... 730
Gansevoort RT (abst) ..... 967
García-Escribano C, Díez-Marqués ML, Gonzáles-Rubio M, Rodrígues-Puyol M, Rodríguez-Puyol D: Somatostatin antagonizes angiotensin II effects on mesangial cell contraction and glomerular filtration ..... 324
Garcia-Perez A *See* Peten EP et al ..... 39:S-55
Gardner PW *See* Llach F et al ..... 899
Garnotel R *See* Borel JP et al ..... 26
Garrett CT *See* Kimmel PL et al ..... 1347
Gaspari F *See* Ruggenenti P et al ..... 706
Gatti M (abst) ..... 757
Gattiani A *See* Santoro A et al ..... 41:S-184
Gattone VH II *See* Cowley BD Jr. et al ..... 522
Gavendo S *See* Shulman LM et al ..... 1397
Geatti O (abst) ..... 760
Gejyo F, Homma N, Arakawa M: Long-term complications of dialysis: Pathogenic factors with special reference to amyloidosis ..... 41:S-78
Genrich LT *See* Strongin AY et al ..... 158
George CRP *See* Llach F et al ..... 899

Germino GG, Somlo S, Weinstat-Saslow D, Reeders ST: Positional cloning approach to the dominant polycystic kidney disease gene, PKD1 ..... 39:S-20
Gerzer R *See* Lauster F et al ..... 41:S-57
Gesualdo L, Ranieri E, Pannarale G, Di Paolo S, Schena FP: Platelet-derived growth factor and proliferative glomerulonephritis ..... 39:S-86
Gesualdo L *See* Pertosa G et al ..... 39:S-149
Gesualdo L *See* Pertosa G et al ..... 41:S-221
Gheerbrant JD *See* Moriniere P et al ..... 41:S-121
Ghio L *See* Ponticelli C et al ..... 1377
Gianoglio B *See* Amore A et al ..... 39:S-41
Giberti D (abst) ..... 760
Gigliola G (abst) ..... 762
Giminez J-J *See* Caillat-Zucman S et al ..... 41:S-157
Giniger MS *See* Tanzer ML et al ..... 66
Giraudo G (abst) ..... 762
Girault A *See* Chauveau P et al ..... 41:S-149
Giucastro G (abst) ..... 760
Giudicissi A (abst) ..... 759
Goggins M *See* Winchester JF et al ..... 40:S-101
Goggins M *See* Winchester JF et al ..... 41:S-174
Goia F (abst) ..... 761
Gokal R: Quality of life in patients undergoing renal replacement therapy ..... 40:S-23
Gokal R *See* Nissenson AR et al ..... 40:S-120
Goldberg GI *See* Strongin AY et al ..... 158
Goldstein DJ *See* Weise WJ et al ..... 359
Gomez RA *See* Tufro-McReddie A et al ..... 615
Gómez-Chiarri M, Ortíz A, Serón D, Gonzalez E, Egido J: The intercrine superfamily and renal disease ..... 39:S-81
Gómez-Chiarri M *See* Egido J et al ..... 39:S-59
Gomez-Garre D *See* Egido J et al ..... 39:S-59
Gómez-Guerrero C *See* Egido J et al ..... 39:S-59
Gonzáles-Rubio M *See* García-Escribano C et al ..... 324
Gonzalez E *See* Egido J et al ..... 39:S-59
Gonzalez E *See* Gómez-Chiarri M et al ..... 39:S-81
Gordon G *See* Sedor JR et al ..... 39:S-65
Gotti E *See* Noris M et al ..... 426
Grant DS *See* Schnaper HW et al ..... 20
Grave W (abst) ..... 970
Greenwood C *See* Sherrard DJ et al ..... 436
Greer JW *See* Powe NR et al ..... 1125
Gregorini G (abst) ..... 759
Gregory MC *See* Zhou J et al ..... 722
Griffiths RI *See* Powe NR et al ..... 1125
Gronich JH *See* Sedor JR et al ..... 39:S-65
Groothoff JW (abst) ..... 968
Gudapaty S *See* Cowley BD Jr. et al ..... 522
Guerin AP *See* London GM et al ..... 41:S-42
Guerrini E (abst) ..... 763
Guler H-P *See* Hirschberg R et al ..... 387
Gunwar S *See* Hudson BG et al ..... 135
Gusmano R (abst) ..... 755
Gusmano R, Perfumo F: Worldwide demographic aspects of chronic renal failure in children ..... 41:S-31
Gusmano R *See* Ponticelli C et al ..... 1377


**H**


Haas M, de Zeeuw D, van Zanten A, Meijer DKF: Quantification of renal low-molecular-weight protein handling in the intact rat (Technical Note) ..... 949
Hack CE *See* Raasveld MHM et al ..... 1140
Haeffner-Cavaillon N, Jahns G, Poignet J-L, Kazatchkine MD: Induction of interleukin-1 during hemodialysis ..... 39:S-139
Haffejee AA (abst) ..... 1180
Hagen EC (abst) ..... 971, 971
Hakim RM *See* Zaoui P et al ..... 1298
Halimi S *See* Cordonnier D et al ..... 41:S-8
Hall CM (abst) ..... 1189
Hall JE: Hyperinsulinemia: A link between obesity and hypertension? (Nephrology Forum) ..... 1402
Halland A (abst) ..... 1184
Hamidou M *See* Esnault VLM et al ..... 1329
Hanck AB *See* Descombes E et al ..... 1319
Hannedouche T *See* Chauveau P et al ..... 41:S-72
Hannedouche T *See* Jungers P et al ..... 41:S-170
Harano K *See* Nomura S et al ..... 1116
Harano T *See* Nomura S et al ..... 1116
Harding MA *See* Cowley BD Jr. et al ..... 522
Harris DR *See* Craelius W et al ..... 535
Hartigan MF *See* Feldman HI et al ..... 1091
Hasegawa H *See* Aoyagi R et al ..... 41:S-111
Hassell JR *See* Noonan DM et al ..... 53
Hattori M, Kim Y, Steffes MW, Mauer SM: Structural-functional relationships in type I mesangiocapillary glomerulonephritis ..... 381
Heidenheim P *See* Lindsay RM et al ..... 41:S-268
Heilbron D *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Heim JM *See* Lauster F et al ..... 41:S-57
Held PJ *See* Feldman HI et al ..... 1091
Henderson LW *See* Leypoldt JK et al ..... 837
Henderson LW *See* Nolph KD et al ..... 40:S-1
Hene RJ (abst) ..... 972
Herbelin A *See* Descamps-Latscha B et al ..... 878
Herbelin A *See* Descamps-Latscha B et al ..... 41:S-135
Herbert RJ *See* Powe NR et al ..... 1125
Hercz G *See* Sherrard DJ et al ..... 436
Herman B *See* Dueymes JM et al ..... 41:S-161
Hertz JM *See* Zhou J et al ..... 722
Heyman SN, Spokes K, Egorin MJ, Epstein FH: Glycine reduces early renal parenchymal uptake of cisplatin ..... 1226
Hidaka S *See* Fujigaki Y et al ..... 567
Hidayat J *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Hill SB *See* Walser M et al ..... 933
Hillebrand G *See* Feucht HE et al ..... 1333
Hirata E *See* Horii Y et al ..... 39:S-71
Hirawa N *See* Toya Y et al ..... 928
Hironaka K, Makino H, Yamasaki Y, Ota Z: Renal basement membranes by ultrahigh resolution scanning electron microscopy ..... 334
Hirschberg R, Brunori G, Kopple JD, Guler H-P: Effects of insulin-like growth factor I on renal function in normal men ..... 387
Hishida A *See* Fujigaki Y et al ..... 567
Hishida A *See* Honda N et al ..... 513
Hoedemaeker PhJ (abst) ..... 968
Hoefsmit ECM *See* Betjes MGH et al ..... 641
Hogg RJ *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Hohnholt M *See* Cheung AK et al ..... 649
Holliday MA *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Homma N *See* Gejyo F et al ..... 41:S-78
Honda M *See* Alexander SR et al ..... 40:S-65

Honda N, Hishida A: Pathophysiology of experimental nonoliguric acute renal failure (Editorial Review) ..... 513
Horigan EA *See* Bruggeman LA et al ..... 1219
Horii Y, Iwano M, Hirata E, Shiiki H, Fujii Y, Dohi K, Ishikawa H: Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis ..... 39:S-71
Hostetter TH *See* Rosenberg ME et al ..... 601
Hostikka SL *See* Tryggvason K et al ..... 38
Hricik DE, Schulak JA, Sell DR, Fogarty JF, Monnier VM: Effects of kidney or kidney-pancreas transplantation on plasma pentosidine ..... 398
Huang S *See* Sedor JR et al ..... 39:S-65
Hudkins KL *See* Alpers CE et al ..... 286
Hudson BG, Kalluri R, Gunwar S, Noelken ME, Mariyama M, Reeders ST: Molecular characteristics of the Goodpasture autoantigen ..... 135
Humes HD, Nakamura T, Cieslinski DA, Miller D, Emmons RV, Border WA: Role of proteoglycans and cytoskeleton in the effects of TGF-$\beta$1 on renal proximal tubule cells ..... 575
Hutchinson JT *See* Feldman HI et al ..... 1091

I

Iadarola GM *See* Piccoli G et al ..... 41:S-282
Iadarola GM *See* Piccoli GB et al ..... 41:S-14
Iannelli S (abst) ..... 756
Ichikawa I *See* Kakinuma Y et al ..... 1229
Ikenaga H, Suzuki H, Ishii N, Itoh H, Saruta T: Role of NO on pressure-natriuresis in Wistar-Kyoto and spontaneously hypertensive rats ..... 205
Imaki H *See* Nosaka K et al ..... 470
Imholz ALT (abst) ..... 969
Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT: Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD ..... 1339
Inagami T *See* Kakinuma Y et al ..... 1229
Ingelfinger JR: Renovascular disease in children (Nephrology Forum) ..... 493
Innis SM *See* Magil AB et al ..... 1243
Isaac J, Berndt TJ, Thothathri V, Tyce GM, Knox FG: Catecholamines and phosphate excretion by the remnant kidney ..... 1021
Iseki K, Kawazoe N, Osawa A, Fukiyama K: Survival analysis of dialysis patients in Okinawa, Japan (1971–1990) ..... 404
Ishii M *See* Toya Y et al ..... 928
Ishii N *See* Ikenaga H et al ..... 205
Ishikawa H *See* Horii Y et al ..... 39:S-71
Ishikawa I: Renal cell carcinoma in chronic hemodialysis patients—A 1990 questionnaire study in Japan . 41:S-167
Ishiyama T *See* Aoyagi R et al ..... 41:S-111
Isidoro C (abst) ..... 762
Isidoro C *See* Roccatello D et al ..... 39:S-144
Isidoro C *See* Roccatello D et al ..... 1150
Itakura H *See* Takemura T et al ..... 918
Itoh H *See* Ikenaga H et al ..... 205
Iwamoto T *See* Toya Y et al ..... 928
Iwano M *See* Horii Y et al ..... 39:S-71

J

Jacobs DWC (abst) ..... 1185
Jacobs J (abst) ..... 1181
Jacobson JE (abst) ..... 1186
Jadoul M, Malghiem J, Vande Berg B, van Ypersele de Strihou C: Ultrasonography of joint capsules and tendons in dialysis-related amyloidosis ..... 41:S-106
Jahns G *See* Haeffner-Cavaillon N et al ..... 39:S-139
Jankelson D (abst) ..... 1185
Janssen WMT (abst) ..... 972
Jevnikar AM *See* Kelly VR et al ..... 39:S-108
Johnson RJ *See* Alpers CE et al ..... 286
Johnson RJ *See* Floege J et al ..... 39:S-47
Johnson RJ *See* Floege J et al ..... 369
Jörres A *See* Topley N et al ..... 226
Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD: Lipoprotein heterogeneity in end-stage renal disease ..... 410
Judith D *See* Moriniere P et al ..... 41:S-121
Jungers P, Zingraff J, Page B, Albouze G, Hannedouche T, Man N-K: Detrimental effects of late referral in patients with chronic renal failure: A case-control study ..... 41:S-170
Jungers P *See* Albouze G et al ..... 41:S-278
Jungers P *See* Caillat-Zucman S et al ..... 41:S-157
Jungers P *See* Chauveau P et al ..... 41:S-72
Jungers P *See* Descamps-Latscha B et al ..... 878

K

Kachko A *See* Majdalani G et al ..... 41:S-131
Kahn D (abst) ..... 1186, 1190
Kaissling B *See* Eckardt K-U et al ..... 815
Kakinuma Y, Fogo A, Inagami T, Ichikawa I: Intrarenal localization of angiotensin II type 1 receptor mRNA in the rat ..... 1229
Kala UK (abst) ..... 1185
Kalluri R *See* Hudson BG et al ..... 135
Kamoun P *See* Chauveau P et al ..... 41:S-72
Kaplan DR *See* Tykocinski ML et al ..... 39:S-120
Kapoor SC *See* Krishna GG et al ..... 1097
Karakiulakis GD *See* Maragoudakis ME et al ..... 147
Karasawa R *See* Sato H et al ..... 430
Kashgarian M *See* Marx M et al ..... 1027
Kaskel FJ *See* Tufro-McReddie A et al ..... 615
Katz A *See* Crary GS et al ..... 140
Kawazoe N *See* Iseki K et al ..... 404
Kazatchkine MD *See* Haeffner-Cavaillon N et al ..... 39:S-139
Kefalides NA, Liotta LA, Neilson EG: Introduction ..... 1
Kefalides NA, Ohno N, Wilson CB: Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen ..... 85
Kefalides NA, Ohno N, Wilson CB, Fillit H, Zabriski J, Rosenbloom J: Identification of antigenic epitopes in type IV collagen by use of synthetic peptides ..... 94
Kelley VR *See* Bloom RD et al ..... 1000
Kelly VR, Diaz-Gallo C, Jevnikar AM, Singer GG: Renal tubular epithelial and T cell interactions in autoimmune renal disease ..... 39:S-108
Kenny AJ *See* Wilkins MR et al ..... 273
Keown P *See* Solez K et al ..... 1058
Kerling A *See* Linke RP et al ..... 41:S-100
Kerr P *See* Canaud B et al ..... 41:S-296
Kerr PG *See* Argilés A et al ..... 630
Kerrigan JR *See* Metzger DL et al ..... 1042
Keshaviah P: Urea kinetic and middle molecule approaches to assessing the adequacy of hemodialysis and CAPD ..... 40:S-28
Kesteloot D (abst) ..... 970

Khan IH, Catto GRD: Long-term complications of dialysis: Infection ..... 41:S-143
Khanna R: Dialysis considerations for diabetic patients ..... 40:S-58
Khoschsorur G *See* Rabl H et al ..... 912
Kiess W *See* Cui S et al ..... 796
Kihara M *See* Toya Y et al ..... 928
Killen PD (abst) ..... 968
Kim D *See* Quigg RJ et al ..... 730
Kim M, Sessler NE, Tembe V, Favus MJ, Bushinsky DA: Response of genetic hypercalciuric rats to a low calcium diet ..... 189
Kim Y *See* Hattori M et al ..... 381
Kimmel PL, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT: Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome ..... 1347
King CH *See* Sedor JR et al ..... 39:S-65
King JA *See* Lush DJ et al ..... 983
Kinoshita Y *See* Nagareda T et al ..... 1363
Kirby JA, Rajasekar MR, Lin Y, Proud G, Taylor RMR: Interaction between T lymphocytes and kidney epithelial cells during renal allograft rejection ..... 39:S-124
Kirkpatrick B *See* Chandran PKG et al ..... 41:S-287
Klahr S *See* Yanagisawa H et al ..... 865
Klahr S *See* Yanagisawa H et al ..... 1068
Kleijburg-van der Keur C (abst) ..... 971
Kleiner DE *See* Brown PD et al ..... 163
Kleinman HK *See* Schnaper HW et al ..... 20
Klotman PE *See* Bruggeman LA et al ..... 1219
Knecht A *See* Shulman LM et al ..... 1397
Knoers N (abst) ..... 971
Knox FG *See* Isaac J et al ..... 1021
Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Løkkegaard N, Rasmussen LS, Lassen A, Krogsgaard K: Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease ..... 1353
Kobayasi S *See* Fujigaki Y et al ..... 567
Koch K *See* Lindsay RM et al ..... 41:S-1
Koch K-M *See* Schindler R et al ..... 712
Kodama T *See* Takemura T et al ..... 918
Koene RAP (abst) ..... 968
Koene RAP *See* Feith GW et al ..... 824
Költringer P *See* Rabl H et al ..... 912
Konieczkowski M *See* Sedor JR et al ..... 39:S-65
Kooman JP *See* Leunissen KML et al ..... 41:S-50
Koomans HA (abst) ..... 967, 970, 972
Koomans HA *See* Boer WH et al ..... 301
Koomen GCM (abst) ..... 968, 969
Koomen GCM *See* Imholz ALT et al ..... 1339
Kooymans-Couthino M *See* Yard BA et al ..... 39:S-133
Kopchick JJ *See* Yang C-W et al ..... 39:S-90
Kopple JD *See* Hirschberg R et al ..... 387
Korbet SM: Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis ..... 40:S-111
Korhonen TK *See* Miettinen A et al ..... 592
Kortas C *See* Lindsay RM et al ..... 41:S-268
Koshikawa S *See* Nakashima Y et al ..... 41:S-88
Koster HPG, van Os CH, Bindels RJM: $Ca^{2+}$ oscillations in the rabbit renal cortical collecting system induced by $Na^+$ free solutions ..... 828
Kotze HF (abst) ..... 1181
Koury ST *See* Eckardt K-U et al ..... 815
Kouw P *See* Leunissen KML et al ..... 41:S-50
Kouw PM (abst) ..... 969
Kramer W *See* Wizemann V et al ..... 40:S-85
Krasnov PA *See* Strongin AY et al ..... 158
Kraybill AL *See* Cowley BD Jr. et al ..... 522
Krediet RT (abst) ..... 968, 969
Krediet RT *See* Betjes MGH et al ..... 641
Krediet RT *See* Imholz ALT et al ..... 1339
Kreisberg JI, Ayo SH: The glomerular mesangium in diabetes mellitus ..... 109
Kren S *See* Rosenberg ME et al ..... 601
Kribben A, Wetzels JFM, Wieder ED, Burke TJ, Schrier RW: New technique to assess hypoxia-induced cell injury in individual isolated renal tubules (Technical Note) ..... 464
Krieg RJ Jr. *See* Metzger DL et al ..... 1042
Krishna GG, Kapoor SC: Potassium supplementation ameliorates mineralocorticoid-induced sodium retention ..... 1097
Krogsgaard K *See* Knudsen F et al ..... 1353
Krüger C *See* Noronha IL et al ..... 682
Kubodera N *See* Finch JL et al ..... 561
Kubota M *See* Nissenson AR et al ..... 40:S-120
Kühn R *See* Endlich K et al ..... 314
Kumano K, Yokota S, Nanbu M, Sakai T: Do cytokine-inducing substances penetrate through dialysis membranes and stimulate monocytes? ..... 41:S-205
Kumar R *See* Lutz W et al ..... 845
Kurokawa K *See* Nosaka K et al ..... 470
Kurtz A *See* Eckardt K-U et al ..... 815
Kurtzman NA *See* Eiam-Ong S et al ..... 1015
Kuwata S *See* Nosaka K et al ..... 470
Kwan JTC, Beer JC, Noonan K, Cunningham J: Parathyroid sensing of the direction of change of calcium in uremia ..... 1104

L

Labadarios D (abst) ..... 1181
Labeeuw M *See* Durozard D et al ..... 885
Ladefoged SD *See* Knudsen F et al ..... 1353
Lafayette RA *See* Mayer G et al ..... 346
Lameire N (abst) ..... 970
Lampugnani MG *See* Dejana E et al ..... 61
Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist ..... 479
Land W *See* Feucht HE et al ..... 1333
Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus ..... 661
Lang MJ *See* Topley N et al ..... 226
Lassen A *See* Knudsen F et al ..... 1353
Laurens W (abst) ..... 968
Lauster F, Heim JM, Drummer C, Fülle H-J, Gerzer R, Schiffl H: Plasma cGMP level as a marker of the hydration state in renal replacement therapy ..... 41:S-57
Lavaud S *See* Chanard J et al ..... 41:S-83
Leaker B *See* Moodie FDL et al ..... 675
Lebkiri B *See* Caillat-Zucman S et al ..... 41:S-157
Ledingham JGG *See* Raine AEG et al ..... 700
Lee DBN *See* Tram KK-T et al ..... 693
Lee EJC *See* Lye WC et al ..... 1357
Leid RW (abst) ..... 971
Lemarec N *See* Chauveau P et al ..... 41:S-149
Leong SO *See* Lye WC et al ..... 1357
Lerch R *See* Sztajzel J et al ..... 41:S-60
Lesavre P *See* Esnault VLM et al ..... 1329

Leski M *See* Sztajzel J et al ..... 41:S-60
Leunissen K (abst) ..... 970
Leunissen KML, Kouw P, Kooman JP, Cheriex EC, deVries PMJM, Donker AJM, van Hooff JP: New techniques to determine fluid status in hemodialyzed patients ..... 41:S-50
Levato G (abst) ..... 757, 757
Lever M *See* Sizeland PCB et al ..... 448
Levine JS *See* Weise WJ et al ..... 359
Levy M: Hepatorenal syndrome'(Nephrology Forum) ..... 737
Levy M, Cernacek P: Renal response to ANP in normal dogs during extreme inhibition of distal $Na^+$ transport ..... 1236
Levy NT (abst) ..... 1180
Leypoldt JK, Henderson LW: Molecular charge influences transperitoneal macromolecule transport ..... 837
Li M (abst) ..... 758, 761
Lianos EA *See* Wu S-H et al ..... 1280
Libetta C (abst) ..... 761
Liggett R *See* Chandran PKG et al ..... 41:S-287
Liguori A (abst) ..... 759
Lin Y *See* Kirby JA et al ..... 39:S-124
Linari F (abst) ..... 760
Lindholm B *See* Bergström J et al ..... 40:S-39
Lindon JC *See* Foxall PJD et al ..... 234
Lindsay RM, Davison A, Koch K, van Ypersele de Strihou C: Introduction ..... 41:S-1
Lindsay RM, Spanner E, Heidenheim P, Kortas C, Blake PG: PCR, Kt/V and membrane ..... 41:S-268
Linke RP, Kerling A, Rail A: Hemodialysis: Demonstration of truncated $\beta_2$-microglobulin in AB-amyloid *in situ* ..... 41:S-100
Linnenweber S *See* Schindler R et al ..... 712
Liotta LA *See* Kefalides NA et al ..... 1
Liotta LA *See* Stracke ML et al ..... 151
Liviano D'Arcangelo G (abst) ..... 756
Ljungberg P *See* Miettinen A et al ..... 592
Llach F, Gardner PW, George CRP, Cairoli O: Aluminum kinetics using bicarbonate dialysate with the sorbent system ..... 899
Llach F *See* Felsenfeld AJ et al ..... 771
Locatelli F (abst) ..... 754
Locatelli F *See* Ponticelli C et al ..... 1377
Logue B *See* May R et al ..... 1156
Løkkegaard N *See* Knudsen F et al ..... 1353
Lolait S *See* Lutz W et al ..... 845
Lolli S (abst) ..... 763
Lombard C (abst) ..... 1182
London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B: Cardiac hypertrophy and arterial alterations in end-stage renal disease: Hemodynamic factors ..... 41:S-42
Lonnemann G: Dialysate bacteriological quality and the permeability of dialyzer membranes to pyrogens ... 41:S-195
Lopez-Armada MJ *See* Egido J et al ..... 39:S-59
Lopez-Pedret J *See* Cases A et al ..... 41:S-217
Loris N (abst) ..... 759
Losi B (abst) ..... 755
Lucia N (abst) ..... 759
Luperini M (abst) ..... 756
Lupi GP (abst) ..... 757
Lupo A (abst) ..... 758
Lush DJ, King JA, Fray JCS: Pathophysiology of low renin syndromes: Sites of renal renin secretory impairment and prorenin overexpression (Editorial Review) ..... 983
Lusvarghi E *See* Di Felice A et al ..... 41:S-201
Lusvarghi E *See* Ponticelli C et al ..... 1377
Luttmann W *See* Topley N et al ..... 226
Lutz W, Sanders M, Salisbury J, Lolait S, O'Carroll A-M, Kumar R: Vasopressin receptor-mediated endocytosis in cells transfected with $V_1$-type vasopressin receptors ..... 845
Lye WC, Leong SO, Lee EJC: Methicillin-resistant *Staphylococcus aureus* nasal carriage and infections in CAPD ..... 1357

**M**

Macaluso M (abst) ..... 756
Madri JA *See* Marx M et al ..... 1027
Maffei S *See* Piccoli G et al ..... 41:S-282
Maffei S *See* Piccoli GB et al ..... 41:S-14
Magder L *See* Walser M et al ..... 933
Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP: Oxidized low-density lipoprotein in experimental focal glomerulosclerosis ..... 1243
Mahé JL *See* Dueymes JM et al ..... 41:S-161
Maiorca R (abst) ..... 755, 759
Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L: Morbidity and mortality of CAPD and hemodialysis ..... 40:S-4
Maiorca R *See* Nissenson AR et al ..... 40:S-120
Majdalani G, Chomant J, Kachko A, Yanai M, Man N-K: Kinetics of technetium-labeled heparin in hemodialyzed patients ..... 41:S-131
Maki S *See* Takemura T et al ..... 918
Makino H *See* Hironaka K et al ..... 334
Malberti F (abst) ..... 761
Malberti F, Surien M, Cosci P: Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol ..... 41:S-125
Malghiem J *See* Jadoul M et al ..... 41:S-106
Mallafre JM *See* Oliva JA et al ..... 41:S-153
Maloney NA *See* Sherrard DJ et al ..... 436
Malvaldi G (abst) ..... 754
Man N-K *See* Albouze G et al ..... 41:S-278
Man N-K *See* Jungers P et al ..... 41:S-170
Man N-K *See* Majdalani G et al ..... 41:S-131
Manas D (abst) ..... 1186, 1190
Mandell J *See* Atala A et al ..... 1081
Mangiarotti G *See* Pacitti A et al ..... 41:S-96
Manieri P (abst) ..... 761
Manili L (abst) ..... 755
Manili L *See* Maiorca R et al ..... 40:S-4
Manning EC *See* Weise WJ et al ..... 359
Manuel A *See* Sherrard DJ et al ..... 436
Manzione A (abst) ..... 761
Maragoudakis ME, Missirlis E, Karakiulakis GD, Sarmonica M, Bastakis M, Tsopanoglou N: Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties ..... 147
Marangella M (abst) ..... 760
Marchais SJ *See* London GM et al ..... 41:S-42
Marcussen N *See* Solez K et al ..... 1058
Margolius LA (abst) ..... 1182
Margolius LP (abst) ..... 1180, 1187, 1190
Margulies IMK *See* Cioce V et al ..... 30
Mariano F *See* Camussi G et al ..... 39:S-32
Marini A (abst) ..... 757
Mariyama M *See* Hudson BG et al ..... 135
Marmer BL *See* Strongin AY et al ..... 158

Martin J-P *See* Esnault VLM et al ..... 1329
Martina G (abst) ..... 761
Martin-Malo A, Velasco F, Rojas R, Castillo D, Rodriguez M, Torres A, Aljama P: Fibrinolytic activity during hemodialysis: A biocompatibility-related phenomenon ..... 41:S-213
Martins M (abst) ..... 1182, 1188
Marumo F *See* Shichiri M et al ..... 443
Marumo F *See* Terada Y et al ..... 1251
Maruyama Y *See* Aoyagi R et al ..... 41:S-111
Marx M, Daniel TO, Kashgarian M, Madri JA: Spatial organization of the extracellular matrix modulates the expression of PDGF-receptor subunits in mesangial cells ..... 1027
Marx M *See* Sterzel RB et al ..... 39:S-26
Masa A (abst) ..... 755
Maschio G (abst) ..... 758
Massara C *See* Piccoli G et al ..... 41:S-282
Massry SG *See* Fadda GZ et al ..... 554
Mastrangelo E (abst) ..... 757
Mastrangelo E *See* Albertazzi A et al ..... 41:S-188
Matumoto A *See* Takemura T et al ..... 918
Mauer SM *See* Hattori M et al ..... 381
Mauer SM *See* Lane PH et al ..... 661
May M (abst) ..... 1180
May R, Logue B, Edwards B, Patel S: An *in vitro* method for the determination of protein turnover in incubated proximal tubule segments (Technical Note) ..... 1156
Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW: Effects of angiotensin II receptor blockade on remnant glomerular permselectivity ..... 346
Mayer U *See* Aumailley M et al ..... 7
Maymo RM *See* Oliva JA et al ..... 41:S-153
Maynard C *See* Cordonnier D et al ..... 41:S-8
Mazzaferro S (abst) ..... 760
Mazzucco G (abst) ..... 763
Mazzucco G *See* Roccatello D et al ..... 1150
McCarthy KJ *See* Couchman JR et al ..... 79
McIntyre S *See* Yamaki M et al ..... 1286
Mehta RL *See* Ward DM et al ..... 41:S-237
Meijer DKF *See* Haas M et al ..... 949
Mellotte GJ *See* Foxall PJD et al ..... 234
Memoli B (abst) ..... 761
Memoli B *See* De Nicola L et al ..... 307
Menè P, Pugliese G, Pricci F, Di Mario U, Cinotti GA, Pugliese F: High glucose inhibits cytosolic calcium signaling in cultured rat mesangial cells ..... 585
Menth M *See* Röckel A et al ..... 41:S-67
Mentre F *See* Mignon F et al ..... 41:S-18
Meola M (abst) ..... 756
Meriggioli M (abst) ..... 756
Mesiti A (abst) ..... 762
Mesiti A *See* Roccatello D et al ..... 1150
Messa P (abst) ..... 760
Metivier F *See* London GM et al ..... 41:S-42
Metzger DL, Kerrigan JR, Krieg RJ Jr., Chan JCM, Rogol AD: Alterations in the neuroendocrine control of growth hormone secretion in the uremic rat ..... 1042
Meyer TW *See* Mayer G et al ..... 346
Meyer TW *See* Narkun-Burgess DM et al ..... 1110
Meyers AM (abst) ..... 1180, 1180, 1182, 1185, 1186, 1187, 1188, 1190
Meyers K (abst) ..... 1185
Meyers KEC (abst) ..... 1184, 1189, 1189, 1189
Michael AF *See* Crary GS et al ..... 140
Michel C *See* Mignon F et al ..... 41:S-18
Miettinen A, Westerlund B, Tarkkanen A-M, Törnroth T, Ljungberg P, Renkonen O-V, Korhonen TK: Binding of bacterial adhesins to rat glomerular mesangium in vivo ..... 592
Mignon F, Michel C, Mentre F, Viron B: Worldwide demographics and future trends of the management of renal failure in the elderly ..... 41:S-18
Milam RA *See* Powe NR et al ..... 1125
Miller D (abst) ..... 1181
Miller D *See* Humes HD et al ..... 575
Miller PL *See* Narkun-Burgess DM et al ..... 1110
Milongo R *See* Cordonnier D et al ..... 41:S-8
Mimran A *See* Mourad G et al ..... 419
Mimran A *See* Valentin J-P et al ..... 1260
Minetti L (abst) ..... 754, 756, 762
Minola E (abst) ..... 754
Minto AW, Fogel MA, Natori Y, O'Meara YM, Abrahamson DR, Smith B, Salant DJ: Expression of type I collagen mRNA in glomeruli of rats with passive Heymann nephritis ..... 121
Minto AW *See* Weise WJ et al ..... 359
Minuz P (abst) ..... 760
Mioli V *See* Carletti P et al ..... 41:S-70
Mion C *See* Argilés A et al ..... 630
Mion C *See* Canaud B et al ..... 41:S-296
Mioni G (abst) ..... 760
Missirlis E *See* Maragoudakis ME et al ..... 147
Miura Y *See* Aoyagi R et al ..... 41:S-111
Molino A (abst) ..... 762
Molino A *See* Roccatello D et al ..... 1150
Molitch ME, Steffes MW, Cleary PA, Nathan DM: Baseline analysis of renal function in the Diabetes Control and Complications Trial ..... 668
Monarca C (abst) ..... 763
Monboisse JC *See* Borel JP et al ..... 26
Monga G (abst) ..... 763
Monin C *See* Sztajzel J et al ..... 41:S-60
Monnens LAH (abst) ..... 971
Monnier VM *See* Hricik DE et al ..... 398
Montanari A (abst) ..... 760
Montinaro V, Di Cillo M, Perissutti S, Serra L, Tedesco F, Rifai A, Schena FP: Modulation of renal production of C3 by proinflammatory cytokines ..... 39:S-37
Montinaro V *See* Pertosa G et al ..... 41:S-221
Montrucchio G *See* Camussi G et al ..... 39:S-32
Moodie FDL, Leaker B, Cambridge G, Totty NF, Segal AW: Alpha-enolase: A novel cytosolic autoantigen in ANCA positive vasculitis ..... 675
Moore LC *See* Tufro-McReddie A et al ..... 615
Moore R: MHC gene polymorphism in primary IgA nephropathy ..... 39:S-9
Moosa MR (abst) ..... 1184, 1186
Moosa R (abst) ..... 1181, 1185
Morassi L (abst) ..... 759
Moriniere P, Esper NE, Viron B, Judith D, Bourgeon B, Farquet C, Gheerbrant JD, Chapuy MC, Van Orshoven A, Pamphile R, Fournier A: Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1alpha(OH) vitamin $D_3$, oral $CaCO_3$ and low dialysate calcium ..... 41:S-121
Morrissey J *See* Yanagisawa H et al ..... 865
Morrissey J *See* Yanagisawa H et al ..... 1068
Moscatelli P (abst) ..... 762
Mosconi L *See* Ruggenenti P et al ..... 706
Motin J *See* Bouffard Y et al ..... 1086

Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants ..... 419
Müller C *See* Topley N et al ..... 226
Murakami K *See* Takemura T et al ..... 918
Murphy JM *See* Yamaki M et al ..... 1286
Murray EJB *See* Tram KK-T et al ..... 693
Murray SS *See* Tram KK-T et al ..... 693
Myburgh JA (abst) ..... 1187, 1190
Myers BD *See* Mayer G et al ..... 346
Myers JC: Differential expression of type I collagen and cellular fibronectin isoforms in endothelial cell variants ..... 45

N

Nagai T *See* Nakashima Y et al ..... 41:S-88
Nagareda T, Kinoshita Y, Tanaka A, Takeda M, Sakano T, Yawata K, Sugimoto T, Nishizawa Y, Terada N: Clinicopathology of kidneys from brain-dead patients treated with vasopressin and epinephrine ..... 1363
Nagase M *See* Fujigaki Y et al ..... 567
Naicker S (abst) ..... 1180, 1186
Naiker IP (abst) ..... 1180
Nakamura T *See* Humes HD et al ..... 575
Nakashima Y, Akizawa T, Nagai T, Koshikawa S: Role of uremic and endothelial factors in the development of $\beta_2$-microglobulin amyloidosis ..... 41:S-88
Nakazato Y *See* Sedor JR et al ..... 39:S-65
Nanbu M *See* Kumano K et al ..... 41:S-205
Nanni Costa A (abst) ..... 756
Napoli C (abst) ..... 759
Naret C *See* Caillat-Zucman S et al ..... 41:S-157
Naret C *See* Chauveau P et al ..... 41:S-149
Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW: Forty-five year follow-up after uninephrectomy ..... 1110
Nathan DM *See* Molitch ME et al ..... 668
Natori Y *See* Minto AW et al ..... 121
Natori Y *See* Weise WJ et al ..... 359
Nauta J (abst) ..... 966
Negri Institute Mario (abst) ..... 759
Neilson EG *See* Kefalides NA et al ..... 1
Neilson EG *See* Wolf G et al ..... 39:S-100
Neilson EG *See* Yee J et al ..... 128
Nestel AW (abst) ..... 1180
Nethononda MR (abst) ..... 1185
Netzer K-O, Pullig O, Frei U, Zhou J, Tryggvason K, Weber M: COL4A5 split site mutation and $\alpha$5(IV) collagen mRNA in Alport syndrome ..... 486
Neuser D *See* Valentin J-P et al ..... 1260
Newton KE *See* Davenport A et al ..... 1313
Nguyen AT *See* Descamps-Latscha B et al ..... 878
Nicholson JK *See* Foxall PJD et al ..... 234
Nielsen S *See* Cui S et al ..... 796
Nieuwhof C (abst) ..... 970
Nikolic-Paterson DJ *See* Lan HY et al ..... 479
Nischt R *See* Aumailley M et al ..... 7
Nishi S-I *See* Sato H et al ..... 430
Nishi T *See* Nosaka K et al ..... 470
Nishi Y *See* Finch JL et al ..... 561
Nishio Y *See* Shichiri M et al ..... 443
Nishizawa Y *See* Nagareda T et al ..... 1363
Nissenson AR: Dialysis therapy in the elderly patient ..... 40:S-51
Nissenson AR, Prichard SS, Cheng IKP, Gokal R, Kubota M, Maiorca R, Riella MC, Rottembourg J, Stewart JH: Non-medical factors that impact on ESRD modality selection ..... 40:S-120
Niutta E (abst) ..... 757
Noakes TD (abst) ..... 1182
Noelken ME *See* Hudson BG et al ..... 135
Noiri E *See* Nosaka K et al ..... 470
Nolan CR *See* Narkun-Burgess DM et al ..... 1110
Nolph KD: Access problems plague both peritoneal dialysis and hemodialysis ..... 40:S-81
Nolph KD, Henderson LW: Introduction ..... 40:S-1
Nomura S, Osawa G, Sai T, Harano T, Harano K: A splicing mutation in the $\alpha$5(IV) collagen gene of a family with Alport's syndrome ..... 1116
Nonoguchi H *See* Terada Y et al ..... 1251
Noonan DM, Hassell JR: Perlecan, the large low-density proteoglycan of basement membranes: Structure and variant forms ..... 53
Noonan K *See* Kwan JTC et al ..... 1104
Noris M, Benigni A, Boccardo P, Gotti E, Benfenati E, Aiello S, Todeschini M, Remuzzi G: Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis ..... 426
Norling LL *See* Tufro-McReddie A et al ..... 615
Norman JE *See* Narkun-Burgess DM et al ..... 1110
Noronha IL, Krüger C, Andrassy K, Ritz E, Waldherr R: *In situ* production of TNF-$\alpha$, IL-$\beta$ and IL-2R in ANCA-positive glomerulonephritis ..... 682
Nortman PJ (abst) ..... 1184
Nosaka K, Nishi T, Imaki H, Suzuki K, Kuwata S, Noiri E, Aizawa C, Kurokawa K: Permeable type I collagen membrane promotes glomerular epithelial cell growth in culture (Technical Note) ..... 470
Nouwen EJ *See* Verstrepen WA et al ..... 1267
Novarini A (abst) ..... 760
Nüssberger J *See* Valentin J-P et al ..... 1260
Nyengaard JR: Number and dimensions of rat glomerular capillaries in normal development and after nephrectomy ..... 1049

O

Obialo CI *See* Carlini RG et al ..... 1010
O'Carroll A-M *See* Lutz W et al ..... 845
Oe PL (abst) ..... 969
Ogura M *See* Shichiri M et al ..... 443
Ohno N *See* Kefalides NA et al ..... 85
Ohno N *See* Kefalides NA et al ..... 94
Oliva JA, Maymo RM, Carrio J, Delgado O, Mallafre JM: Late seroconversion of C virus markers in hemodialysis patients ..... 41:S-153
Oliver J *See* Mayer G et al ..... 346
Olsen S *See* Solez K et al ..... 1058
Olsson C: Prostatic cancer (Nephrology Forum) ..... 955
Omar AA *See* Tufro-McReddie A et al ..... 615
O'Meara YM *See* Minto AW et al ..... 121
O'Meara YM *See* Weise WJ et al ..... 359
Onetti Muda A (abst) ..... 758
Onorato L (abst) ..... 760
Oppermann M *See* Schindler R et al ..... 712
Ordinas A *See* Cases A et al ..... 41:S-217
Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G: Renal endothelin gene expression is increased in remant kidney and correlates with disease progression ..... 354

Orloff JJ, Soifer NE, Fodero JP, Dann P, Burtis WJ: Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure ..... 1371
Ortalda V (abst) ..... 758
Ortíz A *See* Egido J et al ..... 39:S-59
Ortíz A *See* Gómez-Chiarri M et al ..... 39:S-81
Osawa A *See* Iseki K et al ..... 404
Osawa G *See* Nomura S et al ..... 1116
Ota Z *See* Hironaka K et al ..... 334

P

Paape ME *See* Yard BA et al ..... 39:S-133
Pacchiano G (abst) ..... 761
Pacitti A (abst) ..... 761
Pacitti A, Tetta C, Mangiarotti G, Canavese C, Segoloni GP: Beta-2-microglobulin serum profiles in different settings of mass transport and fluid pyrogen content ..... 41:S-96
Page B *See* Jungers P et al ..... 41:S-170
Page WF *See* Narkun-Burgess DM et al ..... 1110
Pagliari B (abst) ..... 754, 755, 761
Paiker J (abst) ..... 1180
Pala E (abst) ..... 761
Palant CE *See* Craelius W et al ..... 535
Palmieri PF *See* Albertazzi A et al ..... 41:S-188
Pamphile R *See* Moriniere P et al ..... 41:S-121
Pan Y *See* Bello-Reuss E et al ..... 173
Pannarale G *See* Gesualdo L et al ..... 39:S-86
Pannier B *See* London GM et al ..... 41:S-42
Parker CJ *See* Cheung AK et al ..... 649
Parker M *See* Dworkin LD et al ..... 808
Parlevliet KJ (abst) ..... 971
Pascoe MD (abst) ..... 1179, 1184
Pascual M, Schifferli JA: Adsorption of complement factor D by polyacrylonitrile dialysis membranes ..... 903
Pasquali M (abst) ..... 760
Pasquali S *See* Ponticelli C et al ..... 1377
Patel S *See* May R et al ..... 1156
Pei Y *See* Sherrard DJ et al ..... 436
Pellicoro JA *See* Bruggeman LA et al ..... 1219
Pellizoni M (abst) ..... 757, 757
Perfumo F (abst) ..... 755
Perfumo F *See* Gusmano R et al ..... 41:S-31
Perico N, Remuzzi G: Role of endothelin in glomerular injury ..... 39:S-76
Perico N *See* Orisio S et al ..... 354
Perico N *See* Ruggenenti P et al ..... 706
Perinotto P (abst) ..... 760
Perissutti S *See* Montinaro V et al ..... 39:S-37
Perobelli L (abst) ..... 758
Perruzza I (abst) ..... 760
Pertosa G, Gesualdo L, Tarantino EA, Ranieri E, Bottalico D, Schena FP: Influence of hemodialysis on interleukin 6 production and gene expression by peripheral blood mononuclear cells ..... 39:S-149
Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP: C5b-9 generation and cytokine production in hemodialyzed patients ..... 41:S-221
Peruccio D *See* Roccatello D et al ..... 39:S-144
Peruzzi L *See* Amore A et al ..... 39:S-41
Pesce CM *See* Yang C-W et al ..... 39:S-90
Peten EP, Striker LJ, Garcia-Perez A, Striker GE: Studies by competitive PCR of glomerulosclerosis in growth hormone transgenic mice ..... 39:S-55
Peten EP *See* Yang C-W et al ..... 39:S-90
Petersen MM *See* Topley N et al ..... 226
Peterson DD *See* Pressman MR et al ..... 1134
Petrarulo M (abst) ..... 760
Petritsch P *See* Rabl H et al ..... 912
Petrucci V (abst) ..... 761
Picciotto G (abst) ..... 762
Piccoli G (abst) ..... 762, 762
Piccoli G, Bonello F, Massara C, Salomone M, Maffei S, Iadarola GM, Stramignoni E, Rosati C, Borca M, Belardi P, Quarello F, Piccoli G, Vercellone A: Death in conditions of cachexia: The price for the dialysis treatment of the elderly? ..... 41:S-282
Piccoli G *See* Piccoli G et al ..... 41:S-282
Piccoli G *See* Piccoli GB et al ..... 41:S-14
Piccoli G *See* Roccatello D et al ..... 39:S-144
Piccoli G *See* Roccatello D et al ..... 1150
Piccoli GB, Quarello F, Bonello F, Salomone M, Triolo G, Maffei S, Iadarola GM, Stramignoni E, Borca M, Beltrame G, Cavalli PL, Piccoli G, Vercellone A: Diabetic patients on dialysis: A changing picture ..... 41:S-14
Pieterse A (abst) ..... 1186
Pignone E (abst) ..... 762
Pimmel P *See* Durozard D et al ..... 885
Pinerolo C (abst) ..... 758, 761
Plaza J *See* Egido J et al ..... 39:S-59
Poignet J-L *See* Chauveau P et al ..... 41:S-149
Poignet J-L *See* Haeffner-Cavaillon N et al ..... 39:S-139
Poli A (abst) ..... 754
Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Casa-Alberighi OD: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome ..... 1377
Pontin AR (abst) ..... 1186, 1190
Pontoriero G (abst) ..... 754
Pontremoli R (abst) ..... 762
Porcellini MG *See* Amore A et al ..... 39:S-41
Port FK: Worldwide demographics and future trends in end-stage renal disease ..... 41:S-4
Pos B (abst) ..... 969
Pougnet M (abst) ..... 1182
Powe NR, Griffiths RI, Greer JW, Watson AJ, Anderson GF, de Lissovoy G, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Early dosing practices and effectiveness of recombinant human erythropoietin ..... 1125
Pozzi C (abst) ..... 761, 763
Pressman MR, Benz RL, Schleifer CR, Peterson DD: Sleep disordered breathing in ESRD: Acute beneficial effects of treatment with nasal continuous positive airway pressure ..... 1134
Pricci F *See* Menè P et al ..... 585
Prichard SS *See* Nissenson AR et al ..... 40:S-120
Proud G *See* Kirby JA et al ..... 39:S-124
Provoost AP (abst) ..... 966
Pugliese F *See* Menè P et al ..... 585
Pugliese G *See* Menè P et al ..... 585
Pullig O *See* Netzer K-O et al ..... 486

Q

Quarello F *See* Piccoli G et al ..... 41:S-282
Quarello F *See* Piccoli GB et al ..... 41:S-14
Quattrocchio G (abst) ..... 762, 762
Quattrocchio G *See* Roccatello D et al ..... 39:S-144
Quattrocchio G *See* Roccatello D et al ..... 1150

Quigg RJ, Galisoff ML, Sneed AE III, Kim D: Isolation and characterization of complement receptor type 1 from rat glomerular epithelial cells ..... 730

R

Raasveld MHM, Bemelman FJ, Schellekens PTA, van Diepen FNJ, van Dongen A, van Royen EA, Hack CE, ten Berge IJM: Complement activation during OKT3 treatment: A possible explanation for respiratory side effects ..... 1140
Rabelink AJ (abst) ..... 972
Rabl H, Khoschsorur G, Colombo T, Petritsch P, Rauchenwald M, Költringer P, Tatzber F, Esterbauer H: A multivitamin infusion prevents lipid peroxidation and improves transplantation performance ..... 912
Racusen LC *See* Solez K et al ..... 1058
Radice A (abst) ..... 763
Ragaiolo M (abst) ..... 761
Ragni G (abst) ..... 760
Rail A *See* Linke RP et al ..... 41:S-100
Raimondi C (abst) ..... 756
Raine AEG, Bedford L, Simpson AWM, Ashley CC, Brown R, Woodhead JS, Ledingham JGG: Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure ..... 700
Raiteri M *See* Dejana E et al ..... 61
Rajasekar MR *See* Kirby JA et al ..... 39:S-124
Rakowski TA *See* Winchester JF et al ..... 41:S-174
Ramakers PLM *See* Bindels RJM et al ..... 295
Rambausek MH, Waldherr R, Ritz E: Immunogenetic findings in glomerulonephritis ..... 39:S-3
Ramdame M *See* Chauveau P et al ..... 41:S-149
Ramjee G (abst) ..... 1179
Ramsaroop R (abst) ..... 1186
Randeree IGH (abst) ..... 1179
Ranieri E *See* Gesualdo L et al ..... 39:S-86
Ranieri E *See* Pertosa G et al ..... 39:S-149
Ranzini C (abst) ..... 755
Rasmussen K *See* Knudsen F et al ..... 1353
Rasmussen LS *See* Knudsen F et al ..... 1353
Ratcliffe PJ *See* Eckardt K-U et al ..... 815
Rauchenwald M *See* Rabl H et al ..... 912
Rayner B (abst) ..... 1181
Rayner BL (abst) ..... 1180, 1183, 1184
Reeders ST *See* Germino GG et al ..... 39:S-20
Reeders ST *See* Hudson BG et al ..... 135
Rees AJ *See* Ryan JJ et al ..... 41:S-226
Reina MC (abst) ..... 763
Reinhardt D *See* Aumailley M et al ..... 7
Reisch J *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Remuzzi G *See* Noris M et al ..... 426
Remuzzi G *See* Orisio S et al ..... 354
Remuzzi G *See* Perico N et al ..... 39:S-76
Remuzzi G *See* Ruggenenti P et al ..... 706
Renkonen O-V *See* Miettinen A et al ..... 592
Rennke HG (abst) ..... 966
Resnati M *See* Dejana E et al ..... 61
Restorick J (abst) ..... 967
Reterink T *See* Yard BA et al ..... 39:S-133
Revert L *See* Cases A et al ..... 41:S-217
Reverter JC *See* Cases A et al ..... 41:S-217
Revillard J-P *See* Chanard J et al ..... 41:S-83
Ribstein J *See* Mourad G et al ..... 419
Ribstein J *See* Valentin J-P et al ..... 1260
Richet G: Edema and uremia from 1827 to 1905: The first faltering steps of renal pathophysiology ..... 1385
Richiardi PM *See* Roccatello D et al ..... 39:S-144
Riella MC *See* Nissenson AR et al ..... 40:S-120
Riethmüller G *See* Feucht HE et al ..... 1333
Rifai A, Sakai H, Yagame M: Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis ..... 39:S-95
Rifai A *See* Montinaro V et al ..... 39:S-37
Rinaldi S *See* Ponticelli C et al ..... 1377
Rini F (abst) ..... 757
Ritz E *See* Noronha IL et al ..... 682
Ritz E *See* Rambausek MH et al ..... 39:S-3
Rivolta E *See* Ponticelli C et al ..... 1377
Rizzoni G *See* Ponticelli C et al ..... 1377
Robba C (abst) ..... 757, 757
Robinet M *See* Albouze G et al ..... 41:S-278
Robino D *See* Winchester JF et al ..... 40:S-101
Robino D *See* Winchester JF et al ..... 41:S-174
Robson RA *See* Sizeland PCB et al ..... 448
Robson S (abst) ..... 1181
Roccatello D (abst) ..... 762, 762
Roccatello D, D'Alfonso S, Peruccio D, Quattrocchio G, Cavalli G, Isidoro C, Piccoli G, Richiardi PM: Induction of mRNA for tumor necrosis factor $\alpha$ in hemodialysis ..... 39:S-144
Roccatello D, Isidoro C, Mazzucco G, Mesiti A, Quattrocchio G, Amore A, Molino A, Coppo R, Sena LM, Piccoli G: Role of monocytes in cryoglobulinemia-associated nephritis ..... 1150
Röckel A, Abdelhamid S, Fiegel P, Menth M, Walb D, Schneditz D: Characterization of "refilling types" by continuous blood volume monitoring during hemodialysis ..... 41:S-67
Rodgers A (abst) ..... 1182
Rodrígues-Puyol M *See* García-Escribano C et al ..... 324
Rodriguez M *See* Martin-Malo A et al ..... 41:S-213
Rodríguez-Puyol D *See* García-Escribano C et al ..... 324
Rogé C *See* Esnault VLM et al ..... 1329
Rogol AD *See* Metzger DL et al ..... 1042
Rojas R *See* Martin-Malo A et al ..... 41:S-213
Rokowski TA *See* Winchester JF et al ..... 40:S-101
Rollin HB (abst) ..... 1180
Romagnoni M (abst) ..... 755
Romano G *See* De Nicola L et al ..... 307
Rombolà G (abst) ..... 754, 756, 762
Romeo G (abst) ..... 758
Roodt JP (abst) ..... 1181
Ropolo R (abst) ..... 762
Rosati C *See* Piccoli G et al ..... 41:S-282
Rosenberg ME, Hostetter TH, Kren S, Chmielewski D: Effect of angiotensin II and norepinephrine on early growth response genes in the rat kidney ..... 601
Rosenbloom J *See* Kefalides NA et al ..... 94
Ross MJ *See* Craelius W et al ..... 535
Rotellar C *See* Winchester JF et al ..... 40:S-101
Rotellar C *See* Winchester JF et al ..... 41:S-174
Rothstein M *See* Carlini RG et al ..... 1010
Rottembourg J: Residual renal function and recovery of renal function in patients treated by CAPD ..... 40:S-106
Rottembourg J *See* Nissenson AR et al ..... 40:S-120
Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression ..... 218
Ruedin P *See* Sztajzel J et al ..... 41:S-60

Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, Bruzzi I, Remuzzi G: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion ..... 706
Rump LC, Schwertfeger E, Schuster MJ, Schaible U, Frankenschmidt A, Schollmeyer PJ: Dopamine $DA_2$-receptor activation inhibits noradrenaline release in human kidney slices ..... 197
Russo D *See* De Nicola L et al ..... 307
Rutishauser W *See* Sztajzel J et al ..... 41:S-60
Ryall R (abst) ..... 1182
Ryan JJ, Beynon HLC, Rees AJ, Cassidy MJD: *In vitro* production of tumor necrosis factor by monocytes cultured from dialysis patients ..... 41:S-226

S

Sabatini S *See* Eiam-Ong S et al ..... 1015
Sabbatini M *See* De Nicola L et al ..... 307
Sacks SH, Warner C, Campbell RD, Dunham I: Molecular mapping of the HLA class II region in HLA-DR3 associated idiopathic membranous nephropathy ..... 39:S-13
Saffioti S (abst) ..... 762
Sai T *See* Nomura S et al ..... 1116
Saiphoo C *See* Sherrard DJ et al ..... 436
Sakai H *See* Rifai A et al ..... 39:S-95
Sakai T *See* Kumano K et al ..... 41:S-205
Sakano T *See* Nagareda T et al ..... 1363
Salant DJ *See* Minto AW et al ..... 121
Salant DJ *See* Weise WJ et al ..... 359
Salisbury J *See* Lutz W et al ..... 845
Salomone M *See* Piccoli G et al ..... 41:S-282
Salomone M *See* Piccoli GB et al ..... 41:S-14
Sam MV (abst) ..... 1182
Samà F (abst) ..... 754, 755
Sanders M *See* Lutz W et al ..... 845
Sands JM *See* Tumlin JA et al ..... 246
Sandstrom DJ (abst) ..... 966
Sanguineti S (abst) ..... 756
Sanna G *See* Santoro A et al ..... 41:S-184
Santoro A, Spongano M, Ferrari G, Bolzani R, Augella F, Borghi M, Briganti M, Cagnoli L, Docci D, Feletti C, Fusaroli M, Gattiani A, Sanna G, Stallone C, Zucchelli P: Analysis of the factors influencing bicarbonate balance during acetate-free biofiltration ..... 41:S-184
Santoro A *See* Zucchelli P et al ..... 41:S-179
Sanz C *See* Cases A et al ..... 41:S-217
Sarmonica M *See* Maragoudakis ME et al ..... 147
Saruta T *See* Ikenaga H et al ..... 205
Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S-I, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases ..... 430
Satriano J *See* Silbiger S et al ..... 853
Schaible U *See* Rump LC et al ..... 197
Schalekamp MADH (abst) ..... 969
Schalkwijk J (abst) ..... 968
Schalkwijk J *See* Feith GW et al ..... 824
Schellekens PTA *See* Raasveld MHM et al ..... 1140
Schellekens PThA (abst) ..... 971
Schena FP, Emancipator SN, Cameron JS: Introduction ..... 39:S-1
Schena FP *See* Gesualdo L et al ..... 39:S-86
Schena FP *See* Montinaro V et al ..... 39:S-37
Schena FP *See* Pertosa G et al ..... 39:S-149
Schena FP *See* Pertosa G et al ..... 41:S-221
Schiaffino E (abst) ..... 758
Schifferli J *See* Sztajzel J et al ..... 41:S-60
Schifferli JA *See* Pascual M et al ..... 903
Schiffl H *See* Lauster F et al ..... 41:S-57
Schiffmann E *See* Stracke ML et al ..... 151
Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch K-M: Gene expression of interleukin-1$\beta$ during hemodialysis ..... 712
Schleifer CR *See* Pressman MR et al ..... 1134
Schlondorff D *See* Silbiger S et al ..... 853
Schmid C (abst) ..... 758
Schnaper HW, Kleinman HK, Grant DS: Role of laminin in endothelial cell recognition and differentiation ..... 20
Schneditz D *See* Röckel A et al ..... 41:S-67
Schneeberger H *See* Feucht HE et al ..... 1333
Schoevaert D *See* Tovey MG et al ..... 39:S-129
Schollmeyer PJ *See* Rump LC et al ..... 197
Schouten JE (abst) ..... 971
Schrama E (abst) ..... 970
Schrier RW *See* Kribben A et al ..... 464
Schroeijers WEM (abst) ..... 967
Schroeijers WEM *See* van den Dobbelsteen MEA et al ..... 544
Schulak JA *See* Hricik DE et al ..... 398
Schulman G: A review of the concept of biocompatibility ..... 41:S-209
Schulze M *See* Schindler R et al ..... 712
Schulze-Lohoff E *See* Sterzel RB et al ..... 39:S-26
Schuster MJ *See* Rump LC et al ..... 197
Schuster S *See* Eckardt K-U et al ..... 815
Schwartz MM, Churchill M, Bidani A, Churchill PC: Reversible compensatory hypertrophy in rat kidneys: Morphometric characterization ..... 610
Schwertfeger E *See* Rump LC et al ..... 197
Scialó A (abst) ..... 761
Scolari MP (abst) ..... 756
Sedor JR, Konieczkowski M, Huang S, Gronich JH, Nakazato Y, Gordon G, King CH: Cytokines, mesangial cell activation and glomerular injury ..... 39:S-65
Seedat YK (abst) ..... 1179, 1179, 1180
Segal AW *See* Moodie FDL et al ..... 675
Segoloni GP *See* Pacitti A et al ..... 41:S-96
Segre GV *See* Sherrard DJ et al ..... 436
Seifert RA *See* Alpers CE et al ..... 286
Sell DR *See* Hricik DE et al ..... 398
Sena LM *See* Roccatello D et al ..... 1150
Sennesael J *See* Verbeelen D et al ..... 41:S-27
Serón D *See* Gómez-Chiarri M et al ..... 39:S-81
Serra L *See* Montinaro V et al ..... 39:S-37
Serventi M (abst) ..... 760
Sesboüé R *See* Esnault VLM et al ..... 1329
Sessler NE *See* Kim M et al ..... 189
Shaldon S: Unanswered questions pertaining to dialysis adequacy in 1992 ..... 41:S-274
Shaldon S *See* Schindler R et al ..... 712
Shan Z *See* Silbiger S et al ..... 853
Shanklin N *See* Allon M et al ..... 212
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure—An evolving disorder ..... 436
Shichiri M, Nishio Y, Ogura M, Suenaga M, Marumo F: Effects of dietary protein restriction on hemodynamics in chronic renal failure ..... 443
Shiiki H *See* Horii Y et al ..... 39:S-71
Shimada H *See* Sato H et al ..... 430

Shimomura M *See* Fujigaki Y et al ..... 567
Shows TB *See* Tryggvason K et al ..... 38
Shulman LM, Yuhus Y, Frolkis I, Gavendo S, Knecht A, Eliahou HE: Glycerol induced ARF in rats is mediated by tumor necrosis factor-alpha ..... 1397
Sidoti A (abst) ..... 754, 755, 761
Silbiger S, Crowley S, Shan Z, Brownlee M, Satriano J, Schlondorff D: Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge ..... 853
Simon P, Ang KS, Cam G, Benziane A, Bonn F: Indices of adequate dialysis in patients hemodialyzed with AN 69 membrane ..... 41:S-291
Simons JL (abst) ..... 966
Simpson AWM *See* Raine AEG et al ..... 700
Singer GG *See* Bloom RD et al ..... 1000
Singer GG *See* Kelly VR et al ..... 39:S-108
Sinico RA (abst) ..... 758, 763
Sizeland PCB, Chambers ST, Lever M, Bason LM, Robson RA: Organic osmolytes in human and other mammalian kidneys ..... 448
Slatnik I *See* Solez K et al ..... 1058
Slatopolsky E *See* Finch JL et al ..... 561
Smith B *See* Minto AW et al ..... 121
Smogorzewski M *See* Fadda GZ et al ..... 554
Sneed AE III *See* Quigg RJ et al ..... 730
Sobel ME *See* Cioce V et al ..... 30
Society of Nephrology Italian (abst) ..... 759
Soifer NE *See* Orloff JJ et al ..... 1371
Soldati L (abst) ..... 757
Solez K, Racusen LC, Marcussen N, Slatnik I, Keown P, Burdick JF, Olsen S: Morphology of ischemic acute renal failure, normal function, and cyclosporine toxicity in cyclosporine-treated renal allograft recipients ..... 1058
Somlo S *See* Germino GG et al ..... 39:S-20
Sonnekus M (abst) ..... 1188
Sorgato G (abst) ..... 755
Sorice P (abst) ..... 759
Soroush M *See* Stracke ML et al ..... 151
Spanner E *See* Lindsay RM et al ..... 41:S-268
Spencer ES *See* Zhou J et al ..... 722
Spokes K *See* Heyman SN et al ..... 1226
Spongano M *See* Santoro A et al ..... 41:S-184
Spurio A (abst) ..... 760
St. John PL *See* Abrahamson DR et al ..... 73
Stad RK (abst) ..... 967
Stallone C *See* Santoro A et al ..... 41:S-184
Stec F *See* Canaud B et al ..... 41:S-296
Steels P (abst) ..... 968
Stefanoni I (abst) ..... 754
Steffes MW *See* Hattori M et al ..... 381
Steffes MW *See* Lane PH et al ..... 661
Steffes MW *See* Molitch ME et al ..... 668
Stefoni S (abst) ..... 756
Steinbrecher UP *See* Magil AB et al ..... 1243
Steinhausen M *See* Endlich K et al ..... 314
Stella P (abst) ..... 757, 757
Stellato T (abst) ..... 763
Sterzel RB, Schulze-Lohoff E, Marx M: Cytokines and mesangial cells ..... 39:S-26
Stetler-Stevenson WG *See* Brown PD et al ..... 163
Stewart JH *See* Nissenson AR et al ..... 40:S-120
Stoermann C *See* Sztajzel J et al ..... 41:S-60
Stoiber E *See* Feldman HI et al ..... 1091
Stracke ML, Soroush M, Liotta LA, Schiffmann E: Cytoskeletal agents inhibit motility and adherence of human tumor cells ..... 151
Stramignoni E *See* Piccoli G et al ..... 41:S-282
Stramignoni E *See* Piccoli GB et al ..... 41:S-14
Stratta P (abst) ..... 763
Strihou CY: Editorial: Worldwide demographics and future trends ..... 41:S-2
Striker GE *See* Peten EP et al ..... 39:S-55
Striker GE *See* Yang C-W et al ..... 39:S-90
Striker LJ *See* Peten EP et al ..... 39:S-55
Striker LJ *See* Yang C-W et al ..... 39:S-90
Strongin AY, Collier IE, Krasnov PA, Genrich LT, Marmer BL, Goldberg GI: Human 92 kDa type IV collagenase: Functional analysis of fibronectin and carboxyl-end domains ..... 158
Struijk DG (abst) ..... 969
Struijk DG *See* Betjes MGH et al ..... 641
Struijk DG *See* Imholz ALT et al ..... 1339
Suenaga M *See* Shichiri M et al ..... 443
Sugimoto T *See* Nagareda T et al ..... 1363
Surachno J (abst) ..... 971
Surien M *See* Malberti F et al ..... 41:S-125
Suzuki H *See* Ikenaga H et al ..... 205
Suzuki H *See* Takemura T et al ..... 918
Suzuki K *See* Nosaka K et al ..... 470
Suzuki S *See* Sato H et al ..... 430
Swanepoel C (abst) ..... 1181, 1182
Swanepoel CR (abst) ..... 1179, 1188, 1189, 1190
Sweeney WE (abst) ..... 966
Swinnen JV *See* Yamaki M et al ..... 1286
Sztajzel J, Ruedin P, Stoermann C, Monin C, Schifferli J, Leski M, Rutishauser W, Lerch R: Effects of dialysate composition during hemodialysis on left ventricular function ..... 41:S-60

## T

Taccini E (abst) ..... 754
Tadros M (abst) ..... 763
Takagi N *See* Toya Y et al ..... 928
Takeda M *See* Nagareda T et al ..... 1363
Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, Kodama T, Suzuki H, Maki S: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases ..... 918
Takeshian A *See* Allon M et al ..... 212
Tan CC *See* Eckardt K-U et al ..... 815
Tan LC *See* Rovin BH et al ..... 218
Tanaka A *See* Nagareda T et al ..... 1363
Tanzer ML, Chandrasekaran S, Dean JW III, Giniger MS: Role of laminin carbohydrates on cellular interactions ..... 66
Tarantino EA *See* Pertosa G et al ..... 39:S-149
Tarantino EA *See* Pertosa G et al ..... 41:S-221
Tardanico R (abst) ..... 759
Tardio S (abst) ..... 760
Tarkkanen A-M *See* Miettinen A et al ..... 592
Taruscia D *See* Carletti P et al ..... 41:S-70
Tateo E (abst) ..... 760
Tatzber F *See* Rabl H et al ..... 912
Taylor RMR *See* Kirby JA et al ..... 39:S-124
Tedesco F *See* Montinaro V et al ..... 39:S-37
Tembe V *See* Kim M et al ..... 189
ten Berge IJM (abst) ..... 971
ten Berge IJM *See* Raasveld MHM et al ..... 1140

Terada N *See* Nagareda T et al ..... 1363
Terada Y, Tomita K, Nonoguchi H, Marumo F: PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney ..... 1251
Testa A *See* Esnault VLM et al ..... 1329
Testou D *See* Albouze G et al ..... 41:S-278
Tetta C, David S, Biancone L, Canino F, Cambi V, Camussi G: Role of platelet activating factor in hemodialysis ..... 39:S-154
Tetta C *See* Di Felice A et al ..... 41:S-201
Tetta C *See* Pacitti A et al ..... 41:S-96
Thanakitcharu P *See* Fadda GZ et al ..... 554
Thea A (abst) ..... 763
Thierauch K-H *See* Topley N et al ..... 226
Thomson PD (abst) ..... 1184, 1185, 1189, 1189, 1189
Thothathri V *See* Isaac J et al ..... 1021
Timbaldi M (abst) ..... 761
Timio M (abst) ..... 763
Timio M *See* Wizemann V et al ..... 40:S-85
Timpl R *See* Aumailley M et al ..... 7
Tira P (abst) ..... 759
Tissot S *See* Bouffard Y et al ..... 1086
Todeschini M *See* Noris M et al ..... 426
Todeschini P (abst) ..... 756
Tolbert E *See* Dworkin LD et al ..... 808
Tolmay FS (abst) ..... 1184
Tomita K *See* Terada Y et al ..... 1251
Toothill C *See* Davenport A et al ..... 1313
Topley N, Jörres A, Luttmann W, Petersen MM, Lang MJ, Thierauch K-H, Müller C, Coles GA, Davies M, Williams JD: Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1$\beta$ and TNF$\alpha$ ..... 226
Törnroth T *See* Miettinen A et al ..... 592
Torres A *See* Martin-Malo A et al ..... 41:S-213
Toso C (abst) ..... 760
Totty NF *See* Moodie FDL et al ..... 675
Toupance O *See* Chanard J et al ..... 41:S-83
Tovey MG, Deglise-Favre A, Schoevaert D: Differential *in situ* expression of cytokine genes in human renal transplantation ..... 39:S-129
Toya Y, Umemura S, Iwamoto T, Hirawa N, Kihara M, Takagi N, Ishii M: Identification and characterization of adenosine $A_1$ receptor-cAMP system in human glomeruli ..... 928
Tram KK-T, Murray SS, Lee DBN, Murray EJB: PTH-induced osteoblast contraction is mediated by cysteine proteases ..... 693
Triolo G *See* Piccoli GB et al ..... 41:S-14
Trombetta M (abst) ..... 760
Trovarelli V (abst) ..... 761
Troy JL (abst) ..... 966
Tryggvason K, Zhou J, Hostikka SL, Shows TB: Molecular genetics of Alport syndrome ..... 38
Tryggvason K *See* Netzer K-O et al ..... 486
Tryggvason K *See* Zhou J et al ..... 722
Tsopanoglou N *See* Maragoudakis ME et al ..... 147
Tufro-McReddie A, Gomez RA, Norling LL, Omar AA, Moore LC, Kaskel FJ: Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney ..... 615
Tuk CW *See* Betjes MGH et al ..... 641
Tumlin JA, Sands JM: Nephron segment-specific inhibition on $Na^+/K^+$-ATPase activity by cyclosporin A ..... 246
Turrin D (abst) ..... 760
Tyce GM *See* Isaac J et al ..... 1021
Tykocinski ML, Kaplan DR: Prospects for anti-rejection therapies based upon CD8-dependent immunoregulation ..... 39:S-120
Tyler P *See* Bello-Reuss E et al ..... 182

U

Uauy R *See* Southwest Pediatric Nephrology Study Group (SPNSG) et al ..... 893
Ueno M *See* Sato H et al ..... 430
Umemura S *See* Toya Y et al ..... 928
Unsworth EJ *See* Brown PD et al ..... 163
Unwin RJ *See* Wilkins MR et al ..... 273

V

VOost BA (abst) ..... 971
Valentin J-P, Ribstein J, Neuser D, Nüssberger J, Mimran A: Effect of monoclonal anti-ANP antibodies on the acute functional adaptation to unilateral nephrectomy ..... 1260
Valerie KC *See* Chan W et al ..... 790
Vallero A (abst) ..... 762
Vallone C (abst) ..... 760
van Acker BAC (abst) ..... 968
van Breda Vriesman P (abst) ..... 970
van Buren M (abst) ..... 967
Van Buuren AJ (abst) ..... 1187, 1187, 1187
Van Damme B (abst) ..... 968
Van De Voorde J (abst) ..... 970
van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Weening JJ, Berden JHM: Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases ..... 454
van den Dobbelsteen MEA (abst) ..... 967
van den Dobbelsteen MEA, van der Woude FJ, Schroeijers WEM, van Es LA, Daha MR: Soluble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells ..... 544
van den Elsen P *See* Yard BA et al ..... 39:S-133
van den Heuvel LPWJ *See* van den Born J et al ..... 454
van der Heijden I (abst) ..... 971
van der Keur C (abst) ..... 971
van der Meer BJM (abst) ..... 969
van der Voort EAM (abst) ..... 966, 971
van der Woude FJ (abst) ..... 967, 970, 971, 971
van der Woude FJ *See* van den Dobbelsteen MEA et al ..... 544
van der Woude FJ *See* Yard BA et al ..... 39:S-133
van Diepen FNJ *See* Raasveld MHM et al ..... 1140
van Dongen A *See* Raasveld MHM et al ..... 1140
van Es LA (abst) ..... 967, 967, 970, 971
van Es LA *See* van den Dobbelsteen MEA et al ..... 544
van Es LA *See* Yard BA et al ..... 39:S-133
van Gijlswijk-Janssen DJ (abst) ..... 967
van Gompel APM (abst) ..... 968
van Gompel APM *See* Feith GW et al ..... 824
van Hooff JP *See* Leunissen KML et al ..... 41:S-50
Van Orshoven A *See* Moriniere P et al ..... 41:S-121
van Os CH (abst) ..... 966
van Os CH *See* Bindels RJM et al ..... 295
van Os CH *See* Koster HPG et al ..... 828
van Rijn HJM (abst) ..... 967
van Rooyen MMB (abst) ..... 1187
van Royen EA *See* Raasveld MHM et al ..... 1140
van Tilborg CA (abst) ..... 972

van Velthuysen M-LF, Veninga A, Bruijn JA, de Heer E, Fleuren GJ: Susceptibility for infection-related glomerulopathy depends on non-MHC genes ..... 623
van Wyk V (abst) ..... 1181
van Ypersele de Strihou C *See* Jadoul M et al ..... 41:S-106
van Ypersele de Strihou C *See* Lindsay RM et al ..... 41:S-1
van Zanten A *See* Haas M et al ..... 949
van Zyl J (abst) ..... 1181
van Zyl-Smit R (abst) ..... 1179, 1183, 1183
Vande Berg B *See* Jadoul M et al ..... 41:S-106
Vangelista A (abst) ..... 759
Vannice JL *See* Lan HY et al ..... 479
Vanrenterghem Y (abst) ..... 968
Varriale A (abst) ..... 759
vd Ouweland A (abst) ..... 971
Veerkamp JH *See* van den Born J et al ..... 454
Velasco F *See* Martin-Malo A et al ..... 41:S-213
Veneroni G (abst) ..... 755
Veninga A *See* van Velthuysen M-LF et al ..... 623
Verbeelen D, de Neve W, der Niepen PV, Sennesael J: Dialysis in patients over 65 years of age ..... 41:S-27
Verbeke M (abst) ..... 970
Vercellone A (abst) ..... 761, 763
Vercellone A *See* Piccoli G et al ..... 41:S-282
Vercellone A *See* Piccoli GB et al ..... 41:S-14
Vercellone. A *See* Camussi G et al ..... 39:S-32
Verdijk M (abst) ..... 971
Verdura C (abst) ..... 763
Verger C *See* Descamps-Latscha B et al ..... 878
Verhaart S (abst) ..... 1180, 1185
Verstrepen WA, Nouwen EJ, Yue XS, De Broe ME: Altered growth factor expression during toxic proximal tubular necrosis and regeneration ..... 1267
Vezzoli G (abst) ..... 763
Viale JP *See* Bouffard Y et al ..... 1086
Vilella E *See* Joven J et al ..... 410
Viljoen HG (abst) ..... 1179, 1183
Vincent C *See* Chanard J et al ..... 41:S-83
Viron B *See* Mignon F et al ..... 41:S-18
Viron B *See* Moriniere P et al ..... 41:S-121
Vitale C (abst) ..... 760

W

Wadee WA (abst) ..... 1180
Waite B (abst) ..... 1186
Walb D *See* Röckel A et al ..... 41:S-67
Waldherr R *See* Noronha IL et al ..... 682
Waldherr R *See* Rambausek MH et al ..... 39:S-3
Walser M, Hill SB, Ward L, Magder L: A crossover comparison of progression of chronic renal failure: Ketoacids versus amino acids ..... 933
Walton CL *See* Brown SA et al ..... 1210
Wantzin P *See* Knudsen F et al ..... 1353
Ward DM, Mehta RL: Extracorporeal management of acute renal failure patients at high risk of bleeding ..... 41:S-237
Ward L *See* Walser M et al ..... 933
Warner C *See* Sacks SH et al ..... 39:S-13
Watson AJ *See* Powe NR et al ..... 1125
Weber M *See* Netzer K-O et al ..... 486
Weening JJ *See* van den Born J et al ..... 454
Weiland H (abst) ..... 1189
Weinstat-Saslow D *See* Germino GG et al ..... 39:S-20
Weise WJ, Natori Y, Levine JS, O'Meara YM, Minto AW, Manning EC, Goldstein DJ, Abrahamson DR, Salant DJ: Fish oil has protective and therapeutic effects on proteinuria in passive Heymann nephritis ..... 359
Weiss M *See* Feucht HE et al ..... 1333
Westerlund B *See* Miettinen A et al ..... 592
Wetzels JFM *See* Kribben A et al ..... 464
Wever PC (abst) ..... 968
Whalley N (abst) ..... 1182, 1188
Whelton PK *See* Powe NR et al ..... 1125
Wieder ED *See* Kribben A et al ..... 464
Wieringa B (abst) ..... 966
Wilcox PA (abst) ..... 1189
Wilkins MR, Unwin RJ, Kenny AJ: Endopeptidase-24.11 and its inhibitors: Potential therapeutic agents for edematous disorders and hypertension (Editorial Review) ..... 273
Will EJ *See* Davenport A et al ..... 1313
Will EJ *See* Davenport A et al ..... 41:S-230
Will EJ *See* Davenport A et al ..... 41:S-245
Willcox PA (abst) ..... 1188
Willems PHGM *See* Bindels RJM et al ..... 295
Williams JD *See* Topley N et al ..... 226
Wilmink JM (abst) ..... 971
Wilson CB *See* Kefalides NA et al ..... 85
Wilson CB *See* Kefalides NA et al ..... 94
Winchester JF, Rotellar C, Goggins M, Robino D, Alijani MR, Rokowski TA, Argy WP: Transplantation in peritoneal dialysis and hemodialysis ..... 40:S-101
Winchester JF, Rotellar C, Goggins M, Robino D, Rakowski TA, Argy WP: Calcium and phosphate balance in dialysis patients ..... 41:S-174
Wizemann V, Timio M, Alpert MA, Kramer W: Options in dialysis therapy: Significance of cardiovascular findings ..... 40:S-85
Wolf G, Neilson EG: Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells ..... 39:S-100
Wong T *See* Chanard J et al ..... 41:S-83
Woodhead JS *See* Raine AEG et al ..... 700
Woolf AS, Bosch RJ, Fine LG: Gene transfer into the mammalian kidney: First steps towards renal gene therapy ..... 39:S-116
Wu C *See* Chung AE et al ..... 13
Wu S-H, Bresnahan BA, Lianos EA: Hemodynamic role of arachidonate 12- and 5-lipoxygenase in nephrotoxic serum nephritis ..... 1280

Y

Yagame M *See* Rifai A et al ..... 39:S-95
Yamaki M, McIntyre S, Murphy JM, Swinnen JV, Conti M, Dousa TP: ADH resistance of LLC-$PK_1$ cells caused by overexpression of cAMP-phosphodiesterase type-IV ..... 1286
Yamasaki Y *See* Hironaka K et al ..... 334
Yanagisawa H, Morrissey J, Klahr S: Bilateral ureteral obstruction alters levels of the G-protein subunits $G_{\alpha s}$ and $G_{\alpha q/11}$ ..... 865
Yanagisawa H, Morrissey J, Klahr S: Protein intake affects levels of G-protein subunits $G_{\alpha i2}$, $G_{\alpha i3}$, and $G_{\beta}$ in rat glomerular membranes ..... 1068
Yanai M *See* Albouze G et al ..... 41:S-278
Yanai M *See* Majdalani G et al ..... 41:S-131

Yang C-W, Striker LJ, Kopchick JJ, Chen WY, Pesce CM, Peten EP, Striker GE: Glomerulosclerosis in mice transgenic for native or mutated bovine growth hormone gene ..... 39:S-90
Yard BA (abst) ..... 970
Yard BA, Kooymans-Couthino M, Reterink T, van den Elsen P, Paape ME, Bruyn JA, van Es LA, Daha MR, van der Woude FJ: Analysis of T cell lines from rejecting renal allografts ..... 39:S-133
Yawata K *See* Nagareda T et al ..... 1363
Yee J, Neilson EG: Immune modulation of biologic systems in renal somatic cells ..... 128
Yokota S *See* Kumano K et al ..... 41:S-205
Yordy MR, Bowen JW: Na, K-ATPase expression and cell volume during hypertonic stress in human renal cells ..... 940
Yoshioka K *See* Takemura T et al ..... 918
Young BA *See* Floege J et al ..... 39:S-47
Young BA *See* Floege J et al ..... 369
Yue XS *See* Verstrepen WA et al ..... 1267
Yuhus Y *See* Shulman LM et al ..... 1397
Yusufi ANK, Christensen S, Dousa TP: Effect of chronic lithium treatment upon the $Na^+$-coupled cotransporters in renal brush border membranes ..... 1074

## Z

Zabriski J *See* Kefalides NA et al ..... 94
Zaoui P, Hakim RM: Natural killer-cell function in hemodialysis patients: Effect of the dialysis membrane ..... 1298
Zaoui P *See* Cordonnier D et al ..... 41:S-8
Zarama M *See* Lan HY et al ..... 479
Zech P *See* Durozard D et al ..... 885
Zeppenfeldt E (abst) ..... 970
Zhou J, Gregory MC, Hertz JM, Barker DF, Atkin C, Spencer ES, Tryggvason K: Mutations in the codon for a conserved arginine-1563 in the COL4A5 collagen gene in Alport syndrome ..... 722
Zhou J *See* Netzer K-O et al ..... 486
Zhou J *See* Tryggvason K et al ..... 38
Zietse R (abst) ..... 969
Zingraff J *See* Descamps-Latscha B et al ..... 878
Zingraff J *See* Jungers P et al ..... 41:S-170
Ziyadeh FN: Renal tubular basement membrane and collagen type IV in diabetes mellitus ..... 114
Zoccali C (abst) ..... 756, 758
Zoja C *See* Orisio S et al ..... 354
Zucchelli P, Santoro A: Correction of acid-base balance by dialysis ..... 41:S-179
Zucchelli P *See* Santoro A et al ..... 41:S-184

# Subject Index For Volume 43


A
Acetate-free biofiltration
bicarbonate balance . . . . . 41:S-184
bicarbonate kinetics (abst) . . . . . 761
efficacy, tolerance of . . . . . 41:S-188
phosphate removal, Mg/Ca balance (abst) . . . . . 755
Acid-base balance
correction by dialysis . . . . . 41:S-179
transport, RCCT-28A kidney cell line . . . . . 173
Acute renal failure
cardiovascular stability, CAVHF, CAVHD . . . . . 41:S-245
cyclosporine, transplantation . . . . . 1058
high bleeding risk patients . . . . . 41:S-237
ischemic, Nephrology Forum . . . . . 1160
mediated by TNF-$\alpha$ . . . . . 1397
nonoliguric . . . . . 513
post-traumatic . . . . . 41:S-235
Acute tubular necrosis
post-transplant morphology . . . . . 1058
Adenosine $A_1$ receptor
antagonist, hypertension, Na excretion, (abst) . . . . . 967
cAMP system in human glomeruli . . . . . 928
ADH-resistant transfected LLC-$PK_1$ cells . . . . . 1286
Adsorption of factor D by polyacrylonitrile . . . . . 903
Adynamic bone disease, aluminum toxicity (abst) . . . . . 754
Albuminuria
anti-GBM nephritis, passive . . . . . 824
anti-GBM nephritis (abst) . . . . . 968
Allografts
failed, RF management outcome . . . . . 41:S-36
monitoring with NMR urinalysis . . . . . 234
rejection, clinical/histological aspects (abst) . . . . . 1188
rejection, EC, T lymphocytes . . . . . 39:S-124
rejection, T cell analysis . . . . . 39:S-133
$\alpha$-enolase, ANCA-positive vasculitis . . . . . 675
$\alpha$1-antitrypsin deficiency in vasculitis . . . . . 1329
Alport syndrome
COL4A5 mutations . . . . . 486, 722, 1116
molecular genetics . . . . . 38
Aluminum
absorption, with Ci-containing calcium (abst) . . . . . 1180
kinetics, bicarbonate dialysate . . . . . 899
post-transplant hemopoiesis . . . . . 1313
toxicity, adynamic bone disease (abst) . . . . . 754
Amino acids
CRF progression . . . . . 933
intra-and extracellular, CAPD, children (abst) . . . . . 755
Amyloidosis
$\beta$-$_2$m, HD . . . . . 41:S-78, 41:S-83, 41:S-88, 41:S-111
$\beta$-$_2$m, HD, ultrasonography . . . . . 41:S-106
renal biopsy study (abst) . . . . . 1179
AN69 membrane dialysis
adequacy indices . . . . . 41:S-291
survival rates . . . . . 41:S-287
Anemia
EPO, CAPD, HD . . . . . 40:S-111
uremic cardiopathy . . . . . 41:S-70
Angiogenesis, basement membrane synthesis . . . . . 147
Angiotensin converting enzyme (ACE) inhibition
Ca antagonist, CsA, antihypertensive therapy . . . . . 419
calcium antagonists, renal injury . . . . . 808
nondiabetic renal disease (abst) . . . . . 967
Angiotensin I
CsA, renin, gene expression . . . . . 615
Angiotensin II
blockade, glomerular permselectivity . . . . . 346
early growth response genes . . . . . 601
modulates proximal tubular cells . . . . . 39:S-100
receptor, PCR localization . . . . . 1251
somatostatin, MC, glomerular filtration . . . . . 324
type 1 receptor mRNA, intrarenal localization . . . . . 1229
Anti-aldosterone drugs, Bartter's syndrome (abst) . . . . . 756
Anti-ANP antibodies, post-nephrectomy natriuresis . . . . 1260
Anti-glomerular basement membrane nephritis
albuminuria . . . . . 824
albuminuria (abst) . . . . . 968
Anti-myeloperoxidase antibodies, vasculitis (abst) . . . . . 763
Anti-neutrophil cytoplasmic antibodies (ANCA)
GN, in situ cytokine production . . . . . 682
GN, silica exposure (abst) . . . . . 759
vasculitis, $\alpha$-enolase . . . . . 675
vasculitis, $\alpha$1-antitrypsin deficiency . . . . . 1329
vasculitis, systemic (abst) . . . . . 759
vasculitis and nephritis (abst) . . . . . 971
Wegener's disease (abst) . . . . . 971
Anti-rejection therapies
CD-8 dependent immunoregulation . . . . . 39:S-120
Antigenic epitopes, collagen IV, synthetic peptides . . . . . 94
Antihypertensive therapy
cyclosporine A, ACEI, calcium antagonist . . . . . 419
renal hemodynamics, proteinuria . . . . . 1210
renal injury . . . . . 808
Apolipoproteins
B-100 in glomeruli . . . . . 430
LDL receptors in human glomeruli . . . . . 918
Atherosclerosis, hyperhomocysteinemia, uremia . . . . . 41:S-72
ATPase enzymes in furosemide therapy . . . . . 1015
Atrial natriuretic peptide (ANP)
antibodies, post-nephrectomy natriuresis . . . . . 1260
extra-natriuretic effects . . . . . 307
response in dogs receiving diuretics . . . . . 1236
Automatized peritoneal dialysis
creatinine, $\beta_2$m (abst) . . . . . 761
Autosomal-dominant polycystic kidney disease (ADPKD)
juvenile, murine mutant . . . . . 1081
positional cloning, PKD1 . . . . . 39:S-20
in the rat . . . . . 522
Autosomal-recessive polycystic kidney disease
epithelial hyperplasia, murine (abst) . . . . . 966
Azathioprine, conversion from cyclosporine (abst) . . . . . 1190

B
Bacterial adhesins binding to glomerular mesangium . . . . . 592
Bartter's syndrome, anti-aldosterone drugs (abst) . . . . . 756
Basement membrane
collagen auto-antibodies . . . . . 85

collagen IV, DM ... 114
glycoprotein, anti-tubular BM nephritis ... 140
hereditary interstitial nephritis (abst) ... 1180
by high resolution SEM ... 334
human neutrophil adhesion/activation ... 26
matrix molecules in ... 121
nidogen, ternary complex formation ... 7
proteoglycans ... 79
structure/variant forms, perlecan ... 53
synthesis, angiogenesis ... 147
$\beta_2$ integrins, neutrophils, HD membranes ... 649
$\beta_2$ microglobulin
amyloidosis, dialysis ... 41:S-78, 41:S-88, 41:S-111
fragments in AB-amyloid *in situ* ... 41:S-100
metabolism, dialysis ... 41:S-83
peritoneal extraction, CAPD, APD (abst) ... 761
transport and fluid pyrogen content ... 41:S-96
Bicarbonate balance
acetate-free biofiltration ... 41:S-184
acetate-free biofiltration (abst) ... 761
Bicarbonate dialysate, aluminum kinetics ... 899
Biocompatibility
cardiovascular stability, HD ... 41:S-230
concept review ... 41:S-209
fibrinolytic activity, HD ... 41:S-213
Biopsy, renal (abst) ... 1179
Bleeding, risk of
arachidonic acid metabolism, platelets (abst) ... 1183
coagulation studies, CAPD (abst) ... 1181
management in ARF ... 41:S-237
renal failure, hormone therapy (abst) ... 1183
Blood pressure
adenosine $A_1$-R antagonist, Na excretion (abst) ... 967
increase, family history (abst) ... 757
loss of nocturnal decline, CRF (abst) ... 757
Blood volume
non-invasive measurement (abst) ... 969
Bone disease
adynamic, aluminum toxicity (abst) ... 754
ESRD and ... 436
HD, calcium/phosphate balance ... 41:S-174
HD, long-term ... 41:S-116, 41:S-121, 41:S-125
HD, mineral metabolism, CAPD ... 40:S-92
Bone resorption, PTH-induced, cysteine proteases ... 693
Brain-dead patients, donor kidneys from ... 1363
Branched-chain amino acids
nephrotic patients (abst) ... 756
Brush border membranes
Li therapy, $Na^+$-cotransporters ... 1074

C

C3 production, cytokines ... 39:S-37
C4d complement fragmentation, renal graft loss ... 1333
C5b-9 and cytokines in HD ... 41:S-221
"Ca-Sandoz" tablets, aluminum toxicity (abst) ... 1180
$Ca^{2+}$ oscillations
renal collecting system, Na-free solutions ... 828
Cachexia in the elderly on dialysis, death by ... 41:S-282
Calcitriol
intravenously in hyperparathyroidism ... 41:S-125
pulsed therapy, histologic effects, HD (abst) ... 760
renal osteodystrophy (abst) ... 754
Calcium
active transport, protein kinase C ... 295
CRF, hyperparathyroidism, hypertension ... 700
cytosolic signaling, glucose, MC ... 585
dialysate concentration, hyperparathyroidism ... 630
dietary, hypercalciuria ... 189
directional changes, PTH, uremia ... 1104
erythrocyte transport, hypercalciuria (abst) ... 763
kinetics, paired filtration dialysis (abst) ... 761
magnesium balance, AFB, phosphate removal (abst) ... 755
phosphate, OCT, hyperparathyroidism ... 561
phosphate balance, dialysis ... 41:S-174
PTH curve, CRF (abst) ... 760
PTH curve, HD (abst) ... 761
Calcium antagonist
converting enzyme inhibitors, renal injury ... 808
cyclosporine A, ACEI, antihypertensive therapy ... 419
Calcium channel blockers, renal hypoperfusion, CsA ... 706
Calcium renal stones
hypercalciuria, intracellular pH (abst) ... 762
Cancer
prostatic, Nephrology Forum ... 955
renal cell carcinoma, incidence ... 41:S-167
transplant patients, incidence (abst) ... 1187
Carboxy-terminal fragments of PTHrP in RF ... 1371
Carboxyl-end domains, fibronectin ... 158
Cardiac function
ARF, hepatic failure, HD ... 41:S-245
biocompatibility, HD ... 41:S-230
effect of dialysate ... 41:S-60
hypertrophy, hemodynamics in ESRD ... 41:S-42
uremia, anemia, rHuEPO ... 41:S-70
Catecholamines
phosphate excretion, remnant kidney ... 1021
CD23, soluble, chronic uremia, dialysis ... 878
cGMP as marker of fluid status, dialysis ... 41:S-57
Children
CAPD ... 40:S-65
CAPD, amino acids (abst) ... 755
CRF, demographics ... 41:S-31
eosinophilia, acute cellular rejection (abst) ... 1189
nephrotic syndrome, clinical aspects (abst) ... 1187
nephrotic syndrome, histological aspects (abst) ... 1187
neuroendocrine control of GH in CRI ... 1042
renovascular disease, Nephrology Forum ... 493
transplantation, compliance study (abst) ... 1189
uremia, growth hormone resistance ... 790
CHIP28 water channel
cDNA isolation in rats (abst) ... 966
Cholesterol, serum, post-transplant (abst) ... 1183
Chronic renal failure
carboxy-terminal fragment, PTHrP ... 1371
children, demographics ... 41:S-31
dietary protein, hemodynamics ... 443
erythroid progenitor, IL-3 response (abst) ... 754
hyperparathyroidism, hypertension, $Ca^{2+}$ ... 700
late referral to dialysis ... 41:S-170
loss of nocturnal decline of BP (abst) ... 757
neuroendocrine control of GH secretion ... 1042
"nondippers" and progression (abst) ... 763
progression, ketoacids, amino acids ... 933
PTH, hypocalcemia ... 771
PTH-calcium curve (abst) ... 760
Cisplatin uptake, reduced by glycine ... 1226
Citrate-Ca preparations, Al absorption (abst) ... 1180
Coagulation studies in CAPD (abst) ... 1181
Cockroft formula, GFR, ERPF estimates (abst) ... 969
COL4A5 mutations in Alport syndrome ... 486, 722, 1116

Collagen I
fibronectin isoforms, endothelial cell variants ..... 45
glomerular epithelial cell culture ..... 470
Collagen IV
antigenic epitopes, synthetic peptides ..... 94
diabetes mellitus, tubular basement membrane ..... 114
Goodpasture syndrome, auto-antibodies ..... 85
ternary complex, laminin, nidogen ..... 7
Collagenase IV, 92 kDa functional analysis ..... 158
Colony stimulating factor-1, lupus nephritis ..... 1000
Color-Doppler study
ureteral jet in renal disease (abst) ..... 756
Complement activation
C5b-9, cytokines, HD ..... 41:S-221
OKT3 treatment, respiratory side effects ..... 1140
PAN membrane, adsorption of factor D ..... 903
Complement C4d fragment
early renal graft loss ..... 1333
Complement receptor type 1
glomerular EC, isolation from ..... 730
C1q antibodies
glomerular inflammation, SLE (abst) ..... 966
Continuous ambulatory peritoneal dialysis (CAPD)
anemia, EPO, HD ..... 40:S-111
assessing adequacy of ..... 40:S-28
children ..... 40:S-65
children, amino acids (abst) ..... 755
creatinine, $\beta_2$m (abst) ..... 761
immuno-effector characteristics ..... 641
intraperitoneal pressure/transport (abst) ..... 969
methicillin-resistant *staphylococcus aureus* ..... 1357
mineral metabolism, bone disease ..... 40:S-92
morbidity and mortality ..... 40:S-4, 40:S-16
nutrition, adequacy of dialysis ..... 40:S-39
osmotic-induced transport ..... 1339
osteocalcin levels (abst) ..... 758
peritonitis (abst) ..... 1180
plasma cGMP as marker of fluid status ..... 41:S-57
protein catabolic rate (abst) ..... 1181
residual renal function and recovery ..... 40:S-106
Copper, urinary, phosphorus, renal stones (abst) ..... 1182
Cortical collecting system, $Na^+$-$Ca^{2+}$ exchange ..... 828
Creatinine
peritoneal extraction, CAPD, APD (abst) ..... 761
Crescentic glomerulonephritis
IL-1 receptor antagonist ..... 479
Cryoglobulinemia
essential mixed (abst) ..... 762
monocytes in, nephritis ..... 1150
Cryoglobulins, human IgMK-IgG and GN (abst) ..... 758
Cyclic AMP (cAMP)
adenosine $A_1$ receptor, human glomeruli ..... 928
phosphodiesterase IV, ADH-resistant cells ..... 1286
Cyclophosphamide therapy for SLE (abst) ..... 1184
Cyclosporine
conversion to azathioprine (abst) ..... 1190
prednisolone, OKT3, transplantation (abst) ..... 971
trial in steroid-resistant NS ..... 1377
Cyclosporine A
antihypertensive therapy ..... 419
inhibition of Na/K-ATPase ..... 246
renal hypoperfusion ..... 706
renin, angiotensin I, gene expression ..... 615
Cyclosporine toxicity
localization of vascular dysfunction (abst) ..... 970
transplant ATN ..... 1058
Cysteine proteases, PTH, osteoblast contraction ..... 693
Cytokines
ANCA-positive GN, in situ production ..... 682
C3 production ..... 39:S-37
genes in transplantation ..... 39:S-129
glomerular cells and cytoskeleton ..... 39:S-32
long-term dialysis, cellular immunity ..... 41:S-135
mesangial cells ..... 39:S-26
mesangial cells, glomerular injury ..... 39:S-65
mesangial cells, lectins ..... 39:S-41
production across the membrane ..... 41:S-205
production in HD, C5b-9 generation ..... 41:S-221
Cytoskeleton
glomerular cells ..... 39:S-32
role in adherence/motility ..... 151
TGF-$\beta$1, proximal tubule cells, proteoglycans ..... 575

**D**

Deafness, sensorineural, Fanconi syndrome (abst) ..... 1187
Demographics
children, CRF ..... 41:S-31
diabetics, dialysis, future trends ..... 41:S-14
diabetics, RF, future trends ..... 41:S-8
dialysis, transplantation, future trends ..... 41:S-2
elderly, RF, future trends ..... 41:S-18
ESRD, future trends ..... 41:S-4
Diabetes
incidence of dialysis ..... 41:S-14
renal hyperfiltration, EDRF ..... 1306
Diabetes Control and Complications Trial (DCCT) ..... 668
Diabetes insipidus
nephrogenic, vasopressin-2R, mutations (abst) ..... 971
Diabetes mellitus
dialysis and ..... 40:S-58
glomerular mesangium ..... 109
RF therapy, future trends ..... 41:S-8
tubular basement membrane, collagen IV ..... 114
Diabetic nephropathy, glucose, MC matrix ..... 853
Dialysate
calcium concentration, hyperparathyroidism ..... 630
effect on LV function ..... 41:S-60
membrane pyrogen permeability ..... 41:S-195
osmolarity, CAPD ..... 1339
ultrafiltration and endotoxin removal ..... 41:S-201
with and without glucose ..... 1086
Dialysis
acid-base correction ..... 41:S-179
$\beta_2$m amyloidosis ..... 41:S-78, 41:S-88, 41:S-111
$\beta_2$m fragments, AB-amyloid *in situ* ..... 41:S-100
$\beta_2$m metabolism ..... 41:S-83
calcium, phosphate balance ..... 41:S-174
cardiovascular findings in ..... 40:S-85
diabetics ..... 40:S-58
diabetics, incidence in ..... 41:S-14
elderly ..... 40:S-51
elderly, death from cachexia ..... 41:S-282
elderly, ethical/socioeconomic aspects ..... 41:S-27
graft stenosis, Gianturco stent ..... 872
late referral to in CRF ..... 41:S-170
long-term, cellular immunity ..... 41:S-135
long-term complications, bone ..... 41:S-116, 41:S-121
long-term complications, infection ..... 41:S-143
osteoarthropathy, dialysis membranes ..... 41:S-111
PAN membrane, factor D adsorption ..... 903
renal cell carcinoma, prevalence ..... 41:S-167

soluble CD23, uremia ..... 878
sorbent regenerative (REDY) ..... 899
survival analysis ..... 404
Dialyzers
leukocyte trapping, immunodepression (abst) ..... 755
Dietary
calcium, hypercalciuria ..... 189
fish oil, proteinuria, passive Heymann nephritis ..... 359
protein, hemodynamics, CRF ..... 443
protein and G-protein ..... 1068
Diuretics, response to ANP in dogs ..... 1236
Dopamine receptor modulation ..... 197
Doppler study of ureteral jet
in renal disease (abst) ..... 756

E
E-64d attenuates PTH effects ..... 693
Edema, contrasted to uremia, 19th century ..... 1385
Edematous disorders, hypertension, endopeptidase ..... 273
EDRF (NO), diabetic renal hyperfiltration ..... 1306
Eicosanoids in nephrotoxic serum nephritis ..... 1280
Elderly
dialysis, death from cachexia ..... 41:S-282
dialysis, ethical/socioeconomic aspects ..... 41:S-27
dialysis therapy ..... 40:S-51
management of RF, future trends ..... 41:S-18
Electrophysiology of nerve conduction
magnetic stimulation, uremia, EPO (abst) ..... 757
End-stage renal disease
cardiac hypertrophy, hemodynamics ..... 41:S-42
demographics/future trends ..... 41:S-4
hyperkalemia treatment/prevention ..... 1197
lipoprotein heterogeneity ..... 410
modality selection, non-medical factors ..... 40:S-120
osteodystrophy ..... 436
sleep apnea therapy ..... 1134
Endocytosis, receptor-mediated with vasopressin ..... 845
Endopeptidase-24.11 ..... 273
Endothelial cells
$\beta$-$_2$m amyloidosis ..... 41:S-88
endothelin-1 release and rHuEPO ..... 1010
integrins ..... 61
recognition/differentiation, laminin ..... 20
variants, fibronectin isoforms, collagen I ..... 45
Endothelin
gene in renal disease ..... 354
glomerular injury ..... 39:S-76
Entactin
biological functions ..... 13
ternary complex formation, basement membrane ..... 7
Epinephrine, renal function, brain-dead patients ..... 1363
Epithelial cells
cultured glomerular, collagen I ..... 470
hyperplasia, murine ARPKD model (abst) ..... 966
T cell interaction, allograft rejection ..... 39:S-124
Erythrocyte as model of kidney tubule cell (abst) ..... 757
Erythroid progenitor
response to IL-3 in CRF (abst) ..... 754
Erythropoietin
anemia, CAPD, HD ..... 40:S-111
cell production during hypoxic hypoxia ..... 815
CNS effects, uremia, electrophysiology (abst) ..... 757
monocytes inhibit production (abst) ..... 1181
Essential hypertension
adenosine $A_1$-R antagonist, Na excretion (abst) ..... 967
Essential mixed cryoglobulinemia (abst) ..... 762
Exercise tolerance, EPO, HD (abst) ..... 1182
Extracellular fluid
non-invasive measurement (abst) ..... 969
Extracellular matrix
MC, heparin, mesangioproliferative nephritis ..... 369
MC subunits, PDGF-receptor moderates ..... 1027
polycystic kidney disease ..... 101
protein kinase C ..... 109
$TXA_2$, $PGI_2$, regulate gene expression ..... 1219

F
5-lipoxygenase expression in GN ..... 39:S-95
Fanconi syndrome (abst) ..... 1185, 1187
Fatty acids, N-3 in membranous nephritis ..... 359
Feline immunodeficiency virus, nephropathy (abst) ..... 754
Fibrinolytic activity
CAPD (abst) ..... 1181
hemodialysis ..... 41:S-213
Fibronectin
end-stage lesions in GS (abst) ..... 968
functional analysis, carboxyl-end domains ..... 158
isoforms, endothelial cell variants, collagen I ..... 45
production, LDL interactions ..... 218
Fish oil, proteinuria, passive Heymann nephritis ..... 359
Flow cytometry
urinary sediment, transplantation (abst) ..... 756
Fluid status
estimating dry weight ..... 41:S-50
extracellular, non-invasive measurement (abst) ..... 969
plasma cGMP as marker, dialysis ..... 41:S-57
Fluid transport
intraperitoneal pressure, CAPD (abst) ..... 969
Focal glomerulosclerosis, oxidized LDLs ..... 1243
Focal segmental glomerulosclerosis
glomerular hypertension (abst) ..... 966
glomerular hypertrophy, renal failure (abst) ..... 758
lysis of visceral EC (abst) ..... 968
Furosemide, renal ATPases and ..... 1015

G
G-protein
protein intake ..... 1068
subunits, ureteral obstruction ..... 865
Gene transfer, mammalian kidney ..... 39:S-116
Gianturco stent for dialysis graft stenosis ..... 872
Glomerular basement membrane
heparan sulfate proteoglycan ..... 454
idiopathic IgA nephropathy (abst) ..... 970
laminin distribution ..... 73
Glomerular binding of bacterial adhesins ..... 592
Glomerular capillaries after nephrectomy ..... 1049
Glomerular cells and cytoskeleton ..... 39:S-32
Glomerular charge selectivity
IgG1/IgG2 clearance ratio (abst) ..... 968
Glomerular disease
heparan sulfate proteoglycan, GBM ..... 454
tumor necrosis factor-$\alpha$ ..... 39:S-59
Glomerular epithelial cells
culture ..... 470
isolation of complement receptor-1 ..... 730
Glomerular filtration
barrier ..... 567
somatostatin, MC, angiotensin II ..... 324
Glomerular filtration rate
accuracy of slope determination (abst) ..... 969

acute potassium loading (abst) ..... 970
hippurate clearance measurement (abst) ..... 969
serial measurement in infants ..... 893
Glomerular hyperfiltration
prostaglandins, IDDM (abst) ..... 760
Glomerular hypertension in fawn-hooded rats (abst) ..... 966
Glomerular hypertrophy
focal segmental glomerulosclerosis, RF (abst) ..... 758
Glomerular inflammation
C1q antibodies, SLE (abst) ..... 966
Glomerular injury
Apo and LDL receptors ..... 918
endothelin ..... 39:S-76
Glomerular mesangium
diabetes mellitus ..... 109
Glomerular permselectivity
angiotensin II blockade ..... 346
Glomerulonephritis
ANCA-positive, in situ cytokine production ..... 682
ANCA-positive, silica exposure (abst) ..... 759
crescentic, IL-1R antagonist ..... 479
experimental mesangioproliferative ..... 369
5-lipoxygenase expression ..... 39:S-95
growth factors, Nephrology Forum ..... 252
human IgMK-IgG cryoglobulins (abst) ..... 758
immunogenetic findings ..... 39:S-3
mesangial proliferative, IL-6 ..... 39:S-71
mesangiocapillary (abst) ..... 1184
mesangiocapillary type I, structure and function ..... 381
proliferative and PDGF ..... 39:S-86
rapidly progressive (abst) ..... 763
urinary excretion of PAF ..... 426
Glomerulopathy, infection-related ..... 623
Glomerulosclerosis
competitive PCR ..... 39:S-55
end-stage, fibronectin lesions (abst) ..... 968
focal segmental (abst) ..... 758, 966, 968
growth hormone induced ..... 39:S-90
Glomerulus, adenosine $A_1$ receptor-cAMP system ..... 928
Glucose
dialysate, content of ..... 1086
mesangial cell matrix ..... 853
mesangial cytosolic calcium ..... 585
Glycine, reduces cisplatin uptake ..... 1226
Glycolate assays
serum and urine, hyperoxalurias (abst) ..... 760
Glycosaminoglycans
urinary excretion, renal stones (abst) ..... 1182
Goodpasture syndrome
auto-antibodies, collagen IV ..... 85
autoantigen ..... 135
Growth factor, expression during regeneration ..... 1267
Growth factor-$\beta$1
renal tubule cells, proteoglycans ..... 575
Growth hormone
induces glomerulosclerosis ..... 39:S-90
neuroendocrine control in CRI ..... 1042
resistance in uremia ..... 790
Guanine nucleotide regulatory proteins (G-proteins)
bilateral ureteral obstruction ..... 865
protein intake and ..... 1068

**H**

Head-out water immersion
renal nerve response (abst) ..... 972
Hemodialysis
access problems ..... 40:S-81
adequacy of ..... 40:S-28, 41:S-274
adequacy of (abst) ..... 1186
anemia, EPO, CAPD ..... 40:S-111
C5b-9 and cytokine production ..... 41:S-221
calcitriol pulsed therapy (abst) ..... 760
complications ..... 41:S-40
complications, infection ..... 41:S-143
dialysate and cardiac function ..... 41:S-60
dialysate with/without glucose ..... 1086
dry weight estimation ..... 41:S-50
exercise training, EPO (abst) ..... 1182
fibrinolytic activity, biocompatibility ..... 41:S-213
fluid status, non-invasive measurement (abst) ..... 969
future trends ..... 41:S-2, 41:S-296
Gianturco stent for stenosis ..... 872
heparin kinetics ..... 41:S-131
hepatic failure, cardiovascular stability ..... 41:S-245
hepatitis B vaccine ..... 41:S-157
hepatitis B viral DNA detection ..... 41:S-161
hepatitis C ..... 1353
hepatitis C (abst) ..... 1185
hepatitis C antibodies ..... 41:S-149
hepatitis C virus markers ..... 41:S-153
IL-1 induction during ..... 39:S-139
IL-1$\beta$, gene expression during ..... 712
IL-6 gene expression ..... 39:S-149
induces neutrophil degranulation ..... 649
late referral to in CRF ..... 41:S-170
LV function, hypertension, uremia (abst) ..... 759
membranes and platelet activation ..... 41:S-217
mineral metabolism, bone disease ..... 40:S-92
morbidity and mortality ..... 40:S-4, 40:S-16
natural killer cell function ..... 1298
NMR spectroscopy, muscle metabolism ..... 885
nutritional aspects ..... 40:S-39, 41:S-261, 41:S-268
plasma cGMP as marker of fluid status ..... 41:S-57
platelet activating factor ..... 39:S-154
refilling types characterized ..... 41:S-67
renal cell carcinoma incidence ..... 41:S-167
TNF-$\alpha$ mRNA induction ..... 39:S-144
transplantation ..... 40:S-101
vascular access morbidity, US ..... 1091
vitamin supplementation ..... 1319
Hemoglobin, aluminum post-transplant ..... 1313
Hemolytic uremic syndrome
blood group P1 A (abst) ..... 1184
Heparan sulfate proteoglycan, GBM ..... 454
Heparin
kinetics, HD ..... 41:S-131
mesangioproliferative glomerulonephritis ..... 369
Hepatic failure
ARF, cardiovascular stability ..... 41:S-245
Hepatitis B
PCR detection of viral DNA, in dialysis ..... 41:S-161
vaccine, HLA-linked response ..... 41:S-157
Hepatitis C
hemodialysis ..... 41:S-149, 41:S-153, 1353
hemodialysis (abst) ..... 1185
Hepatorenal syndrome, Nephrology Forum ..... 737
Hereditary interstitial nephritis (abst) ..... 1180
Hereditary nephropathy (abst) ..... 1185
High resolution scanning electron microscopy (SEM) ..... 334
Hippurate clearance measurements
Cockroft formula (abst) ..... 969

HIV nephropathy
animal model (abst) ... 754
viral genome ... 1347
Homocysteine, uremia, atherosclerosis ... 41:S-72
Hypercalciuria
idiopathic, erythrocyte Ca transports (abst) ... 763
indapamide (abst) ... 1188
low calcium diet ... 189
pH regulation, calcium renal stones (abst) ... 762
X-linked hypophosphatemic rickets, RF (abst) ... 758
Hypercholesterolemia
idiopathic membranous nephropathy (abst) ... 1183
Hyperhomocysteinemia, uremia, atherosclerosis ... 41:S-72
Hyperinsulinemia
obesity, hypertension, Nephrology Forum ... 1402
Hyperkalemia
ESRD, treatment, prevention ... 1197
insulin, epinephrine ... 212
Hyperlipidemia, post-transplant (abst) ... 1183
Hyperoxalurias
serum and urine glycolate assays (abst) ... 760
Hyperparathyroidism
αcalcidol in dialysis ... 41:S-121
HD, bone complications ... 41:S-116
hypertension, CRF, $Ca^{2+}$ ... 700
intravenous calcitriol ... 41:S-125
lowering Ca dialysate ... 630
OCT, phosphate, calcium metabolism ... 561
primary adenomatous, tubular dysfunction (abst) ... 1185
secondary, $1,25(OH)_2D_3$ therapy (abst) ... 1186
Hypertension
CRF, hyperparathyroidism, $Ca^{2+}$ ... 700
endopeptidase-24.11 ... 273
essential, adenosine $A_1$-R antagonist (abst) ... 967
family history (abst) ... 757
HD, LV function, uremia (abst) ... 759
hyperinsulinemia, obesity, Nephrology Forum ... 1402
rHuEPO therapy ... 1010
Hypertonic stress in human renal cells ... 940
Hypocalcemia, PTH, chronic renal failure ... 771
Hypokalemic metabolic alkalosis
furosemide induced ... 1015
Hypotension
hypovolemia induced (abst) ... 969
refilling types characterized, HD ... 41:S-67
Hypoxic hypoxia, EPO-producing cells during ... 815
Hypoxic injury in single cells ... 464

I
I-hippuran renogram, mathematical modeling (abst) ... 972
Idiopathic membranous nephropathy
genetic susceptibility ... 39:S-13
hypercholesterolemia (abst) ... 1183
IgA nephropathy
antibodies, antigen characterization (abst) ... 761
idiopathic (abst) ... 970
IgA binding, rat MC (abst) ... 967
induced by rat IgA antibodies (abst) ... 967
MHC gene polymorphism ... 39:S-9
Immune complexes
IL-6 production, MC ... 544
renal somatic cells ... 128
Immuno-effector characteristics
peritoneal cells, CAPD ... 641
Immunodeficiency
leukocyte trapping in dialyzers (abst) ... 755
long-term dialysis, cellular immunity ... 41:S-135
soluble CD23, uremia, dialysis ... 878
Immunogentics in GN ... 39:S-3
Indapamide for hypercalciuria (abst) ... 1188
Infants, serial GFR ... 893
Infection
glomerulopathy related ... 623
long-term dialysis complication ... 41:S-143
mycobacterial, transplantation (abst) ... 1189
Injury
glomerular, Apo and LDL receptors ... 918
glomerular, cytokines, mesangial cell ... 39:S-65
glomerular, endothelin ... 39:S-76
hypoxic in single cells ... 464
post-traumatic ARF ... 41:S-235
renal, antihypertensive therapy ... 808
Insulin, fasting hyperkalemia, epinephrine ... 212
Insulin-dependent diabetes mellitus
interstitial expansion ... 661
prostaglandins, glomerular filtration (abst) ... 760
Insulin-like growth factor I
renal function, normal men ... 387
uremia, nutrition, children ... 790
Insulin-like growth factor II
receptors in rat kidney ... 796
Intercrines in renal disease ... 39:S-81
Interleukin-1
crescentic glomerulonephritis ... 479
induction during hemodialysis ... 39:S-139
mesangial cell activation ... 39:S-65
Interleukin-1α
IL-6 production, proximal tubular EC (abst) ... 970
Interleukin-1β
gene expression during HD ... 712
human peritoneal mesothelial cell IL-6 ... 226
production, ANCA-positive GN ... 682
Interleukin-2R
in situ production, ANCA-positive GN ... 682
Interleukin-3
erythroid progenitor response, CRF (abst) ... 754
Interleukin-6
gene expression, HD ... 39:S-149
mesangial proliferation ... 39:S-71
production, MC, immune complexes ... 544
production, proximal tubular EC (abst) ... 970
synthesis, human peritoneal mesothelial cells ... 226
Interleukin-8
mesangial cell activation ... 39:S-65
International Society of Nephrology, Constitution ... 973
Interstitial cells
PDGF-R and mesangial cells ... 286
Interstitial expansion in IDDM ... 661
Interstitial nephritis, hereditary (abst) ... 1180
Intra-abdominal pressure
CAPD, fluid/protein transport (abst) ... 969
peritoneal dialysis ... 40:S-75
Iothalamate infusion
serial GFR measurement, infants ... 893
Ischemic acute renal failure, Nephrology Forum ... 1160

J
Juvenile cystic kidneys, murine mutant ... 1081

K
67 kDa laminin receptor, binding to laminin ... 30

72 kDa type IV procollagenase/TIMP-2 complex ..... 163
Ketoacids
  CRF progression ..... 933
  serum levels, nephrotic patients (abst) ..... 756
Kidneys from brain-dead patients
  clinicopathology ..... 1363
Kt/V
  membrane and protein catabolic rate ..... 41:S-268
  urea modeling ..... 41:S-252
  urea modeling, protein catabolic rate ..... 41:S-278
  urea modeling (abst) ..... 1186

L
12-and 5-lipoxygenases
  nephrotoxic serum nephritis ..... 1280
Laminin
  carbohydrate role, cellular interactions ..... 66
  distribution in GBM ..... 73
  endothelial cell recognition/differentiation ..... 20
  receptor, interaction with 67 kilodalton ..... 30
  ternary complex, collagen IV, nidogen ..... 7
  variants ..... 2
Lectins and cultured mesangial cells ..... 39:S-41
Left ventricular function
  dialysate composition and ..... 41:S-60
  diastolic, HD, hypertension, uremia (abst) ..... 759
Left ventricular hypertrophy
  ESRD ..... 41:S-42
  uremia, anemia, rHuEPO ..... 41:S-70
Leukocyte trapping in dialyzers (abst) ..... 755
Lipid peroxidation, multivitamins, transplantation ..... 912
Lipoproteins
  Apo receptors in human glomeruli ..... 918
  heterogeneity in end-stage renal disease ..... 410
Lithium
  reabsorption, prostaglandin synthesis ..... 301
  renal $Na^+$-cotransporters, brush border membrane ... 1074
Low-density lipoproteins
  experimental FGS ..... 1243
  MC interactions ..... 218
Low-molecular-weight protein, quantification ..... 949
Low renin syndromes, pathophysiology ..... 983
Lupus nephritis, induction with CSF-1 ..... 1000

M
Macrophages, CSF-1 and nephritis ..... 1000
Magnesium
  Ca balance, AFB, phosphate removal (abst) ..... 755
Matrix gene expression in sprouting endothelium ..... 45
Matrix molecules in basement membrane ..... 121
Medicare ESRD program data ..... 1091
Membranes, hemodialysis
  adequacy of, AN69 ..... 41:S-291
  cytokine production, monocyte stimulation ..... 41:S-205
  dialysate quality, pyrogen permeability ..... 41:S-195
  Kt/V, protein catabolic rate ..... 41:S-268
  natural killer cell function ..... 1298
  neutrophil degranulation, $\beta_2$ integrins ..... 649
  osteoarthropathy ..... 41:S-111
  platelet activation ..... 41:S-217
  survival rates, AN69 ..... 41:S-287
Membranous nephritis, N-3 fatty acids ..... 359
Mesangial cells
  cytokines and ..... 39:S-26
  glucose inhibits cytosolic calcium signaling ..... 585
IgA binding (abst) ..... 967
IL-1, IL-8, glomerular injury ..... 39:S-65
immune complexes, IL-6 production ..... 544
LDL interactions ..... 218
lectins ..... 39:S-41
matrix, diabetes mellitus, glucose ..... 853
mechano-activated channels ..... 535
PDGF-R and interstitial cells ..... 286
PDGF-R subunits in ..... 1027
proliferation ..... 39:S-47
proliferation, heparin, nephritis ..... 369
proliferation, IL-6 ..... 39:S-71
somatostatin, ang II, glomerular filtration ..... 324
Mesangiocapillary glomerulonephritis
  randomized therapeutic trial (abst) ..... 1184
  type I, structure and function ..... 381
Methicillin-resistant *staphylococcus aureus*, CAPD ..... 1357
Microalbuminuria, NIDDM (abst) ..... 762
Mineral metabolism, bone disease, CAPD, HD ..... 40:S-92
Mineralocorticoids
  Na retention, K supplementation ..... 1097
Molecular charge influences peritoneal transport ..... 837
Monocytes
  cryoglobulinemia, nephritis ..... 1150
  inhibit EPO production (abst) ..... 1181
  stimulation, cytokine production ..... 41:S-205
  TNF release ..... 41:S-226
Morphology of transplant ATN ..... 1058
Multivitamins and transplantation ..... 912
Murine cystic kidney mutant ..... 1081
Muscle weakness, NMR spectroscopy, HD ..... 885
Mycobacterial infection, transplantation (abst) ..... 1189

N
N-3 fatty acids, membranous nephritis ..... 359
$Na^+$-$Ca^{2+}$ exchange system
  cortical collecting system ..... 828
$Na^+$-cotransporters
  lithium therapy, BBM ..... 1074
Na excretion
  adenosine $A_1$-R antagonist, hypertension (abst) ..... 967
Na/K-ATPase
  cell volume, hypertonic stress ..... 940
  cyclosporin A ..... 246
  furosemide therapy and ..... 1015
Na/K pump
  extrarenal potassium ..... 1197
$Na^+$ transport
  inhibition, ANP response in dogs ..... 1236
Nasal continuous positive airway pressure
  ESRD, sleep apnea ..... 1134
Natriuresis
  post-nephrectomy, anti-ANP antibodies ..... 1260
Natural killer cells
  hemodialysis, dialysis membrane ..... 1298
  long-term dialysis, cellular immunity ..... 41:S-135
Nephrectomy
  anti-ANP antibodies, natriuresis ..... 1260
  forty-five year follow-up ..... 1110
  glomerular capillaries after ..... 1049
Nephritis
  anti-GBM nephritis, albuminuria ..... 824
  anti-tubular basement membrane ..... 140
  interstitial hereditary (abst) ..... 1180
  lupus, induction with CSF-1 ..... 1000

macrophages and CSF-1 ..... 1000
monocytes in cryoglobulinemia ..... 1150
nephrotoxic serum, eicosanoids ..... 1280
passive Heymann ..... 121, 359
Nephrogenic diabetes insipidus
vasopressin-2 receptor, gene mutations (abst) ..... 971
Nephropathy
diabetic ..... 853
feline immunodeficiency virus (abst) ..... 754
hereditary (abst) ..... 1185
HIV, animal model (abst) ..... 754
HIV, viral genome ..... 1347
Nephrotic syndrome
children, clinical aspects (abst) ..... 1187
children, histological aspects (abst) ..... 1187
erythrocyte altered charge (abst) ..... 1179
HIV, viral genome ..... 1347
ketoacid serum levels (abst) ..... 756
steroid-resistant idiopathic, cyclosporine ..... 1377
Nephrotoxic serum nephritis, eicosanoids ..... 1280
Neuroendocrine control of GH secretion in CRI ..... 1042
Neutrophils
adhesion/activation, basement membranes ..... 26
degranulation, $\beta_2$ integrins, HD membranes ..... 649
long-term dialysis, cellular immunity ..... 41:S-135
Nidogen
ternary complex formation, basement membrane ..... 7
Nitric oxide
diabetic renal hyperfiltration ..... 1306
pressure-natriuresis ..... 205
NMR spectroscopy
allograft monitoring ..... 234
uremic muscle metabolism ..... 885
Non-insulin dependent DM, microalbuminuria (abst) .... 762
Nonenyzmatic glycation of mesangial matrix ..... 853
Nonoliguric acute renal failure ..... 513
Noradrenaline, dopamine receptor modulation ..... 197
Norepinephrine
early growth response genes, Ang II ..... 601
Nutrition
adequacy of, dialysis ..... 40:S-39, 41:S-261, 41:S-268
uremia, GH resistance ..... 790

O
$1,25\text{-}(OH)_2D_3$
effect on monocytes, macrophages (abst) ..... 762
hyperparathyroidism, OCT, phosphate, Ca ..... 561
hyperparathyroidism therapy (abst) ..... 1186
$1\alpha(OH)$ vitamin $D_3$
hyperparathyroidism, dialysis ..... 41:S-121
22-oxacalcitriol
hyperparathyroidism, phosphate, Ca ..... 561
Obesity, hyperinsulinemia Nephrology Forum ..... 1402
Okinawa Dialysis Study (OKIDS) ..... 404
OKT3 treatment
prednisolone, cyclosporine (abst) ..... 971
respiratory side effects ..... 1140
Osmolytes, organic ..... 448
Osmotic-induced transport during CAPD ..... 1339
Osteoarthropathy and dialysis membranes ..... 41:S-111
Osteocalcin levels with CAPD (abst) ..... 758
Osteodystrophy, renal
calcitriol (abst) ..... 754
ESRD (abst) ..... 436

P
Paired filtration dialysis, Ca kinetics (abst) ..... 761
Pancreas-kidney transplantation
plasma pentosidine ..... 398
Pancreatic islets, PTH, cytosolic calcium ..... 554
Parathyroid hormone (PTH)
calcium relation curve, analysis (abst) ..... 761
calcium relation curve, CRF (abst) ..... 760
chronic renal failure ..... 771
cytosolic calcium in pancreatic islets ..... 554
directional changes in Ca, uremia ..... 1104
HD, bone complications ..... 41:S-116
osteoblast contraction, cysteine proteases ..... 693
related protein, carboxy-terminal fragment, CRF ..... 1371
Passive anti-GBM nephritis, albuminuria ..... 824
Passive Heymann nephritis
collagen I, glomeruli ..... 121
fish oil, proteinuria ..... 359
PDGF-receptor subunits in mesangial cells ..... 1027
Peanut-lectin (+) cells, RCCT-28A cell line ..... 182
Pentosidine, plasma, post-transplant ..... 398
Peptic ulcer disease, post-transplant (abst) ..... 1190
Peptides, synthetic, antigenic epitopes ..... 94
Percutaneous transvenous angioplasty
Gianturco stent ..... 872
Peritoneal cells
immuno-effector characteristics ..... 641
mesothelial, IL-6 ..... 226
Peritoneal dialysis
access problems ..... 40:S-81
automatized (abst) ..... 761
increased intra-abdominal pressure ..... 40:S-75
molecular charge, macromolecular transport ..... 837
platelets, fibrinolysis/coagulation (abst) ..... 1181
SLE patients (abst) ..... 1181
transplantation ..... 40:S-101
Peritonitis
CAPD (abst) ..... 1180
incidence (abst) ..... 755
Y flush before fill system (abst) ..... 1180
Perlecan ..... 53
Phosphate
calcium, OCT, hyperparathyroidism ..... 561
calcium balance, AFB, magnesium (abst) ..... 755
calcium balance, dialysis ..... 41:S-174
excretion, catecholamines, remnant kidney ..... 1021
Phosphorus, urinary copper, renal stones (abst) ..... 1182
Plasma pentosidine, post-transplant ..... 398
Platelet activating factor
hemodialysis ..... 39:S-154
urinary excretion, GN ..... 426
Platelet activation
CAPD, fibrinolytic, coagulation studies (abst) ..... 1181
HD membranes and ..... 41:S-217
Platelet-derived growth factor
proliferative glomerulonephritis ..... 39:S-86
receptor, MC and interstitial cells ..... 286
Polyacrylonitrile (PAN) membrane
complement factor D ..... 903
Polycystic kidney disease
extracellular matrix ..... 101
juvenile, murine mutant ..... 1081
Polymerase chain reaction
$AT_1$ receptor ..... 1251
competitive, glomerulosclerosis ..... 39:S-55

Polytetrafluoroethylene (PTFE) grafts (abst) ..... 1186
Potassium loading, acute
tubuloglomerular feedback (abst) ..... 970
Potassium supplementation, Na excretion ..... 1097
Prednisolone, OKT3, cyclosporine (abst) ..... 971
Pregnancy and renal disease (abst) ..... 759
Prejunctional dopamine receptors ..... 197
Pressure-natriuresis, nitric oxide ..... 205
Primary adenomatous hyperparathyroidism
tubular dysfunction (abst) ..... 1185
Profunda femoris-saphenous PTFE graft (abst) ..... 1186
Prorenin overexpression
renin secretory impairment ..... 983
Prostacyclin, thromboxane $A_2$, ECM gene expression .. 1219
Prostaglandins
glomerular hyperfiltration, IDDM (abst) ..... 760
synthesis inhibition and Li clearance ..... 301
Prostatic cancer, Nephrology Forum ..... 955
Protein
dietary, G-protein ..... 1068
dietary, hemodynamics, CRF ..... 443
Protein catabolic rate
CAPD (abst) ..... 1181
Kt/V, membrane ..... 41:S-268
Kt/V, urea modeling ..... 41:S-278
Protein kinase C
active calcium transport ..... 295
in extracellular matrix ..... 109
Protein transport
intraperitoneal pressure, CAPD (abst) ..... 969
Protein turnover in proximal tubules ..... 1156
Proteinase 3 ANCA antigen
Wegener's disease (abst) ..... 971
Proteinuria
antihypertensive therapy, diabetic dogs ..... 1210
fish oil, passive Heymann nephritis ..... 359
Proteoglycans
basement membrane development ..... 79
perlecan ..... 53
Proximal tubular necrosis
altered GF, regeneration ..... 1267
Proximal tubule cells
angiotensin II modulation ..... 39:S-100
IGF-II receptors in rat kidney ..... 796
protein turnover ..... 1156
TGF-$\beta$1, proteoglycans ..... 575
Pseudo-retinitis pigmentosa
Fanconi syndrome (abst) ..... 1187
PTFE (polytetrafluoroethylene) grafts (abst) ..... 1186
Pulmonary nocardiosis, post-transplant (abst) ..... 1188

**Q**

Quantification of renal LMWP handling ..... 949

**R**

RCCT-28A kidney cell line
acid-base transport ..... 173
peanut-lectin (+) cells ..... 182
Receptor-endocytosis of vasopressin receptor ..... 845
Recombinant human erythropoietin (rHuEPO)
anemia, uremic cardiopathy ..... 41:S-70
dosing and effectiveness ..... 1125
endothelin-1 release by EC ..... 1010
exercise tolerance, HD (abst) ..... 1182
Refilling types in hemodialysis ..... 41:S-67
Regulatory volume increase, Na/K-ATPase expression ... 940
Renal cell carcinoma, incidence of ..... 41:S-167
Renal disease
apolipoprotein(a) and apoB-100 ..... 430
Doppler study of ureteral jet (abst) ..... 756
endothelin gene ..... 354
intercrines ..... 39:S-81
lipoprotein heterogeneity ..... 410
pathophysiology, 19th century ..... 1385
pregnancy and (abst) ..... 759
Renal failure
future management trends, DM ..... 41:S-8
future management trends, elderly ..... 41:S-18
glomerular hypertrophy, FGS (abst) ..... 758
management outcome, failed allografts ..... 41:S-36
thrombocytopenia (abst) ..... 1179
Renal function
baseline analysis, DCCT ..... 668
insulin-like growth factor I, normal men ..... 387
production of C3 ..... 39:S-37
residual and recovery, CAPD ..... 40:S-106
Renal hyperfiltration, diabetes, EDRF ..... 1306
Renal hypertrophy, reversible, compensatory ..... 610
Renal hypoperfusion, CsA, calcium channel blockers .... 706
Renal nerves, head-out water immersion (abst) ..... 972
Renal plasma flow, Cockroft formula (abst) ..... 969
Renal somatic cells, immune system mechanisms ..... 128
Renal stones
calcium ..... 762
glycosaminoglycans, urinary excretion (abst) ..... 1182
urinary copper, phosphorus (abst) ..... 1182
Renal transport enzymes, furosemide therapy ..... 1015
Renin-angiotensin system
CsA, gene expression ..... 615
PCR localization of $AT_1$ receptor ..... 1251
prorenin overexpression ..... 983
Renogram, mathematical modeling (abst) ..... 972
Renovascular disease in children, Nephrology Forum .... 493
Respiratory side effects, OKT3 treatment ..... 1140
Rheumatoid vasculitis
anti-lactoferrin antibodies (abst) ..... 971
Rickets, X-linked hypophosphatemic, RF (abst) ..... 758

**S**

Sensorineural deafness, Fanconi syndrome (abst) ..... 1187
Serial GFR in infants ..... 893
Serotonin, effects on renal vessels ..... 314
Silica exposure, ANCA-positive GN (abst) ..... 759
Simvastatin
in hypercholesterolemia (abst) ..... 1183
Sleep apnea, ESRD ..... 1134
Smith, Homer ..... 171
Sodium excretion, potassium supplementation ..... 1097
Somatostatin
angiotensin II, MC, glomerular filtration ..... 324
Sorbent regenerative dialysis (REDY) ..... 899
Stents, Gianturco ..... 872
Steroid-resistant idiopathic NS, cyclosporine ..... 1377
Systemic lupus erythematosus (SLE)
cyclophosphamide therapy (abst) ..... 1184
glomerular inflammation, C1q antibodies (abst) ..... 966
nephritis induction with CSF-1 ..... 1000
peritoneal dialysis patients (abst) ..... 1181

**T**
T cells
analysis, allograft rejection ..... 39:S-133
tubular EC interactions ..... 39:S-108
T lymphocytes
dialysis, cellular immunity ..... 41:S-135
EC, allograft rejection ..... 39:S-124
Ternary basement membrane complexes ..... 7
Thalamate clearance measurements
Cockroft formula (abst) ..... 969
Thrombocytopenia in renal failure (abst) ..... 1179
Thromboxane $A_2$, prostacyclin, ECM gene expression .. 1219
Toxic proximal tubular necrosis, GF, regeneration ..... 1267
Transforming growth factor-$\beta$1
renal tubule cells, proteoglycans ..... 575
Transperitoneal macromolecular transport ..... 837
Transplantation
aluminum, hemopoiesis ..... 1313
cellular infiltrates, immunology of (abst) ..... 1186
children, acute cellular rejection (abst) ..... 1189
children, compliance study (abst) ..... 1189
complement C4d fragment, graft function ..... 1333
CsA, antihypertensive therapy ..... 419
CsA, renal hypoperfusion, Ca channel blockers ..... 706
cyclosporine, azathioprine (abst) ..... 1190
cyclosporine, prednisolone, OKT3 (abst) ..... 971
cytokine gene expression ..... 39:S-129
demographics/future trends ..... 41:S-2
flow cytometry, urinary sediment (abst) ..... 756
malignancy in recipients (abst) ..... 1187
morphology of ATN ..... 1058
multivitamins, lipid peroxidation ..... 912
mycobacterial infection (abst) ..... 1189
peptic ulcer disease (abst) ..... 1190
peritoneal dialysis, HD ..... 40:S-101
plasma pentosidine after ..... 398
pulmonary nocardiosis (abst) ..... 1188
quality of life ..... 40:S-23
serum cholesterol changes (abst) ..... 1183
Trauma as cause of ARF ..... 41:S-235
Tubular basement membrane, collagen IV, DM ..... 114
Tubular dysfunction
primary adenomatous hyperparathyroidism (abst) .... 1185
Tubular epithelial cells
T cell interactions ..... 39:S-108
Tubular necrosis
toxic proximal, GF, regeneration ..... 1267
Tubule cells, erythrocyte as model of (abst) ..... 757
Tubuloglomerular feedback
acute potassium loading (abst) ..... 970
Tubulointerstitial nephritis antigen
anti-tubular BM nephritis ..... 140
Tumor cells, cytoskeletal role ..... 151
Tumor necrosis factor
release by monocytes ..... 41:S-226
Tumor necrosis factor-$\alpha$
glomerular disease pathogenesis ..... 39:S-59
human peritoneal mesothelial cell IL-6 ..... 226
mediates ARF ..... 1397
mRNA in hemodialysis ..... 39:S-144
in situ production, ANCA-positive GN ..... 682

**U**
Ultrafiltration
endotoxin removal from dialysate ..... 41:S-201
Ultrahigh resolution scanning electron microscopy ..... 334
Ultrasonography, amyloidosis ..... 41:S-106
Uninephrectomy
anti-ANP antibodies, natriuresis ..... 1260
forty-five year followup ..... 1110
natriuresis, anti-ANP antibodies ..... 1260
Urea kinetic modeling ..... 41:S-252, 41:S-278, 1186
Uremia
$\beta$-$_2$m, long-term dialysis ..... 41:S-83, 41:S-88
cardiac hypertrophy, hemodynamics ..... 41:S-42
cardiopathy, anemia, rHuEPO ..... 41:S-70
contrasted to edema, 19th century ..... 1385
EPO, electrophysiology (abst) ..... 757
growth hormone resistance, nutrition ..... 790
hyperhomocysteinemia, atherosclerosis ..... 41:S-72
LV function, HD, hypertension (abst) ..... 759
NMR spectroscopy, muscle metabolism ..... 885
prolonged bleeding times (abst) ..... 1183
PTH sensing and directional changes in Ca ..... 1104
soluble CD23, dialysis ..... 878
Ureteral jet in renal disease
Doppler study (abst) ..... 756
Ureteral obstruction, G-protein subunits ..... 865

**V**
Vascular access for HD
Gianturco stent ..... 872
morbidity in US ..... 1091
profunda femoris-saphenous PTFE graft (abst) ..... 1186
Vasculitis
anti-myeloperoxidase (MPO) antibodies (abst) ..... 763
Vasculitis, rheumatoid
anti-lactoferrin antibodies (abst) ..... 971
Vasculitis, systemic
ANCA-positive ..... 675, 682
ANCA-positive, $\alpha$1-antitrypsin deficiency ..... 1329
ANCA-positive (abst) ..... 759
Vasopressin
receptor-mediated endocytosis ..... 845
renal function, brain-dead patients ..... 1363
Vasopressin-2 receptor
gene mutations, diabetes insipidus (abst) ..... 971
Visceral epithelial cell lysis, FSGS (abst) ..... 968
Vitamin supplementation, hemodialysis ..... 1319

**W**
Wegener's granulomatosis
anti-lactoferrin antibodies (abst) ..... 971
cANCA antigen proteinase 3 (abst) ..... 971

**Y**
Y flush before fill system
peritonitis, CAPD (abst) ..... 1180